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General introduction and outline of this thesis
INTRODUCTION
Thyroid cancer is the most prevalent endocrine malignancy, estimated to account for 96% 
of cancers of the endocrine system and 66% of deaths due to cancers of the endocrine 
system in 2012.[1] The incidence of thyroid cancer throughout the world seems to be 
increasing. In part the increased incidence might be explained by more frequent and 
improved diagnostic imaging, thereby identifying so called “incidentalomas”. However, 
the number of patients that die due to this disease also increases. The current incidence 
in Europe is 49/1.000.000 per year, with a nearly 3 times higher incidence in women.[2]
Thyroid cancer is a heterogeneous disease which is classified into differentiated 
forms of thyroid carcinoma (DTC), undifferentiated (anaplastic) thyroid carcinoma 
(ATC) and medullary thyroid carcinoma (MTC). DTC and ATC together are classified 
as non-medullary thyroid cancer (NMTC, Table 1). Differentiated thyroid carcinoma is 
by far the most common type (95%), and includes papillary (PTC) (80%) and follicular 
(FTC) subtypes (10-15%). Furthermore oncocytic or Hurthle cell metaplasia can occur 
in PTC and FTC due to accumulation of mitochondria in the tumor cells. The latter is 
recognised as pink cytoplasmic colouring in routine hematoxyline and eosin tissue 
staining. To complicate the distinction of NMTC also follicular variants of PTC (FVPTC) 
are recognized. The majority of DTCs are slowly progressive, and, when identified at 
an early stage, most frequently cured with adequate surgical management and post-
operative radioactive iodine 131-I ablation therapy (RAI). Metastatic DTC that has 
become inoperable or refractory to radioactive iodine therapy however, is associated 
with a poor survival (Table 1). NMTC cancers that are refractory to RAI therapy mostly 
comprise a subset of PTCs with activating BRAF gene variants and oncocytic variants 
of FTC (FTC-OV).[3] Remarkably FTC-OV is very low frequent in consecutive series of 
NMTC. MTCs and especially ATCs metastasize in up to 50% of patients, thus giving an 
even worse prognosis.[4] Furthermore ATC present itself as a rapidly
expanding cervical mass, that is often irresectable and leads to death within three 
months after diagnosis. Results of conventional treatment modalities (radiotherapy 
and/or chemotherapy) are disappointing, although there are exceptions. Therefore, 
new therapies are needed. As a result of the increasing knowledge of the biologic 
basis for thyroid cancer development, therapeutic agents that target involved biologic 
abnormalities have been identified. Based on these insights multiple clinical trials have 
been performed in the past decade. In this introduction we describe new treatment 
modalities in RAI refractory NMTC and MTC.
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Table1: Thyroid cancer: tumor type, age, prevalence and survival













Medullary 10-60 5% 75% 10%
Anaplastic >60 5-10% <5% 0
MOLECULAR PATHOGENESIS OF NMTC
For an overview of the signaling pathways involved in thyroid cancer and described 
below, see Figure 1.
Figure 1 Signaling pathways involved in thyroid tumorigenesis
 
PTC
Genetically classic PTC is characterized by either activating BRAF variants (mostly 
V600E) or rearranged during transfection (RET) proto-oncogene rearrangements leading 
to the fusion of the RET tyrosine kinase domain to the 5’ end of a variety other genes 
that are constitutively active in follicular thyroid cells. This results in the generation 
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of a variety of chimeric oncogenes and proteins denoted RET/PTC whose expression 
is under the control of promoters provided by the fused genes, and thus leading to 
ligand-independent activation of RET in papillary thyroid cancer.[5] To date, 12 of these 
chimeric RET/PTC proteins have been described. These RET/PTC gene fusions occur 
in 16 to 25% of PTC cases. Normal functioning BRAF is a putative downstream signal 
transducer for the RET/PTC fusion products. RET/PTC gene fusions are often found in 
pediatric PTC, either being unexplained or being the result from nuclear plant accidents 
as seen in Tsernobyl or recently in Fukushima. PTC with gene fusions at later ages can 
alternatively be the late result of medically administered radiation therapy. Gene fusions 
involving the neurotrophic tyrosine kinase receptor (NTRK) genes lead to transcription 
of chimeric Trk proteins, resulting in subsequent activation of intracellular signaling 
molecules, including RAS, PI3K, and MAPK, thereby stimulating cellular proliferation, 
differentiation, and survival. NTRK gene rearrangements are found in 1-5% of papillary 
thyroid carcinomas, especially in patients with a history of radiation exposure.[6-10] 
However especially at early ages PTCs are mostly sensitive to the given RAI therapies, 
thereby not posing a problem of disease recurrence.
In benign thyroid cells BRAF is an important regulator of thyroid-specific protein 
expression and proliferation.[11] Constitutively activated BRAF through mutation 
is responsible for the development of papillary thyroid carcinoma (PTC), that can 
potentially progress towards anaplastic carcinoma. Kebebew et al. reported significant 
associations of BRAF V600E with recurrent and persistent disease with a higher rate 
of lymph node metastasis and higher TNM stage in PTC and [12]. BRAF was therefore 
initially considered to be an attractive target for therapy in PTC and ATC with activating 
V600E BRAF variants.[13]
The role of the anaplastic lymphoma kinase (ALK) gene rearrangements as 
oncogenic drivers has been well established in preclinical models including transgenic 
mouse models [14,15]. ALK is a receptor tyrosine kinase (RTK) that activates the MAPK/
ERK and PI3K/AKT pathways, promoting cell proliferation and survival. Various ALK 
fusions (EML4-ALK, GFPT1-ALK, TFG-ALK, and STRN-ALK) are reported in thyroid 
cancer patient tumors [16,17].
FVPTC
An option is to classify FVPTC only when there is a complete absence of “papillae” 
and only the nuclear features of PTC are seen (orphan Annie’s eyes, and nuclear 
indentation). When being strict about this morphological distinction no BRAF V600E 
variants or RET/PTC gene fusions are found in FVPTC. More often RAS (HRAS, NRAS, 
KRAS) gene variants or Paired Box 8 /peroxisome proliferator-activated receptor gamma 
(PAX8/PPARɣ) gene rearrangements are identified. These molecular alterations are also 
encountered in FTC (see below).
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FTC classically shows RAS (NRAS or HRAS) or chromosomal translocation leading to 
a PAX8/PPARɣ gene rearrangement. The transcription factor PAX8 plays a role in the 
expression of multiple thyroid specific genes. The PAX8/PPARɣ  gene rearrangement is 
found in 30-40% of follicular thyroid carcinomas. This rearrangement exerts a negative 
effect on the tumor suppressor PPARɣ and activates genes responsive to PAX8.[18-22]
FTC-OV
In FTC-OV gene variants or fusions in cancer driver genes are relatively rare although 
those found (e.g. FLCN, MEN1, mTOR, PTEN, PIK3CA, TP53, and TSC2) are frequently 
involved in metabolic switches. Possibly additional tumor drivers need to be identified. 
Using a new method for DNA content analysis in combination with single nucleotide 
polymorphism (SNP) technology it was demonstrated that many FTC-OV actually show 
a near-homozygous genome (NHG) in which a phase of near-haploidization is followed 
by endoreduplication or genome doubling of the entire NHG[23-26]. The observations 
regarding a NHG have been confirmed by others [27,28]
ADDITIONAL GENE ALTERATIONS IDENTIFIED IN NMTC 
CANCERS
In comparison with other types of non-thyroid cancers in differentiated PTC (and FTC) 
only few additional gene variations can be found. These comprise either variants 
in PIK3CA and PTEN or human (h)-TERT gene promoter variants. TERT promoter 
mutations are seen in ATC (45-73%), PDTC (40%), FTC (14%) and PTC (9%) and can occur 
concomitantly with MAPK-pathway mutations.[29-32] TERT mutations are associated 
with aggressive clinicopathological behavior and a high risk of recurrent disease, 
particularly when accompanied by a BRAF mutation.[33]
It has been suggested that alterations in DNA repair mechanism are involved 
in progression to aggressive forms of PTC.[34]. For instance CHEK2 and PPM1D gene 
variations can occur. CHEK2 is a tumor suppressor gene involved in preserving genome 
stability by repairing DNA double strand breaks. PPM1D is a phosphatase that inhibits 
p53-mediated transcription and apoptosis.[35,36]
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MOLECULAR PATHOGENESIS OF MTC
Activating RET mutations are present in more than 95% of hereditary MTC cases and 
in 20 to 50% of sporadic MTC cases. Several mutational hotspots of the RET gene have 
been described to be tumorigenic. Furthermore, a common specific activating point 
mutation, M918T, appears to be a strong negative prognostic indicator for metastasis-
free survival and survival (OS). Ten-year survival was approximately 45% in subjects 
with a confirmed M918T mutation, while it is reported to be as high as 90% in absence 
of the mutation.[37] In up to 68% of patients without a RET mutation, RAS mutations 
have been found with HRAS and KRAS variants being most frequently observed.[38-41] 
In addition to RET and RAS, the vascular endothelial growth factor receptor (VEGFR) 
and MET proto-oncogenes may be implicated in the pathogenesis of MTC. Transduction 
of thyroid cells with mutant RET results in upregulation of MET.[42] Finally mTOR, an 
effector of the PI3K/AKT pathway, plays an important role in the development of MTCs.
[43]
MOLECULAR PATHOGENESIS OF POORLY DIFFERENTIATED 
AND ATC
ATC either derives from PTC with V600E BRAF mutations or from FTC-OV. In resected 
ATC specimen often only after extensive sampling these more differentiated foci with 
either PTC or FTC are encountered. Additional TP53 gene variants are then driving the 
aggressive ATC tumor fractions. In 9% of poorly differentiated, 4% of anaplastic and 1 
% of papillary thyroid cancers fusion of the striatin (STRN) gene and ALK gene have 
been reported.[44]
RAS/RAF/MAPK PATHWAY IN THYROID CANCER
In a review of 11 studies in thyroid cancer, it was noted that up to 50% of follicular and 
12% of FTC-OV cell malignancies contained RAS mutations.[45] The RAF proteins are 
cytoplasmic serine/threonine protein kinases that are downstream effector molecules 
of RAS. Of these, BRAF is the most efficient at phosphorylating mitogen activated 
protein kinase (MAPK) and is important in proliferative as well as apoptotic pathways.
[46] Point mutations leading to BRAF signaling independent of binding to RAS as seen 
in PTC underlines the significance of the RAS/RAF/MAPK pathway in thyroid cancer.[47] 
The PI3K/AKT pathway on the other hand plays an important role in cell proliferation 
and survival and has been found by others to be aberrantly activated in thyroid tumors.
[48-51] An important player in this pathway is the PI3KCA subunit that in turn is also 
regulated by RAS. In a study by Hou et al., a progressive activation of the PI3K/AKT 
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pathway and associated methylation of PTEN, known to suppress this pathway, was 
found in thyroid adenomas, follicular and anaplastic thyroid cancers.[52]
ANGIOGENESIS IN THYROID CANCER
Concomitantly with MAPK pathway mutations in human thyroid cancer, BRAF V600E 
is associated with VEGF overexpression, which in turn is associated with increasing 
tumor stage and invasiveness.[53] In 1997, Soh et al. observed extensive angiogenesis 
in thyroid cancer cells that had been xenografted into mice. By using cell lines from 
human differentiated thyroid cancers (including FTC-OV) and MTC they noted a higher 
expression of vascular endothelial growth factor (VEGF) mRNA and protein in thyroid 
cancer in comparison to normal thyroid tissue.[54]
NEW TREATMENT MODALITIES IN THYROID CARCINOMA
As a result of the increasing knowledge of the biologic basis for thyroid cancer 
development, therapeutic agents that target these biological abnormalities have been 
identified. Multiple clinical trials have been performed in the past decade (table 2).
I. TYROSINE KINASE INHIBITORS
Monotarget kinase inhibitors
Gefitinib (ZD1839) is an oral Epidermal Growth Factor Receptor (EGFR) TKI. The EGFR is 
highly expressed in malignant thyroid tissue and mutations of the EGFR gene have been 
described in thyroid cancer. Moreover, EGFR contributes to RET activation, signaling 
and growth stimulation and is associated with poor prognosis in DTC.[55] Pennell et al. 
studied the effectiveness of gefitinib in a phase II trial with a mixed cohort of thyroid 
cancer patients. Four percent of patients showed disease reduction. However, this 
was not qualified as partial response. Overall, 24% of patients achieved stable disease 
lasting at least 24 weeks. Median progression free survival was almost 16 weeks, with 
the exception of MTC patients, in which the median PFS was less than 12 weeks.[56] 
Gefitinib does not have a registration for disseminated thyroid cancer.
AZD6244 is a potent, selective, non-competitive inhibitor of MEK1/2 that has been 
studied in a phase I study and has shown interesting activity in 2 advanced thyroid 
cancer patients with stable disease for at least 5 months.[57] A phase II trial conducted 
in advanced DTC patients showed a partial response in 3% of patients, 66% of patients 
had stable disease and the median PFS was 32 weeks.[58]
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Multikinase inhibitors
Axitinib (AG-013736) is an oral TKI that effectively blocks all of the VEGFRs. One of 5 
patients with thyroid carcinoma included in a phase I trial experienced tumor shrinkage, 
which however, was not qualified as a partial response.[59] A phase II trial by Cohen et al. 
studied the efficacy of axitinib in advanced or metastatic thyroid carcinoma of any histology 
(30 PTC, 15 FTC and 11 MTC). A partial response was seen in 31% of the DTC patients 
and 18% of the MTC patients. Stable disease lasting more than 16 weeks was reported in 
38% and the median PFS was 18.1 months.[60] Another phase II study in 52 DTC patients 
reported a PR and SD >16 weeks in 18 (35%) patients. The median PFS was 16 months, the 
median OS 27 months.[61]. However, axitinib has not been registered for thyroid cancer. 
 Motesanib (AMG 706) is an oral TKI targeting the VEGFR 1-3, RET and c-KIT. 
In a phase I trial by Rosen et al. a 50% overall response rate was observed in patients 
with advanced thyroid carcinoma.[62] Based on these results a multicenter phase II trial 
was initiated, testing the efficacy of motesanib therapy in patients with progressive 
DTC and progressive or symptomatic MTC. In 14% of the DTC patients partial response 
was confirmed, and another 35% of these previously progressive patients maintained 
stable disease for at least 24 weeks. The median response duration was 40 weeks.
[63] In a phase II trial in MTC patients by Schlumberger et al. only 2% of patients had 
confirmed partial response, but stable disease for at least 24 weeks was reported in 48% 
of patients. Median PFS was 48 weeks.[64]
 Vandetanib (ZD 6474) is an oral TKI that targets VEGFR 2 and 3, RET and EGFR. 
Vandetanib effectively inhibits RET/PTC3 chromosomal translocations found in some 
PTC and M918T RET mutations occurring in MEN2B-associated and some sporadic 
MTC.[65] In a phase II trial, Wells et al. studied the efficacy of vandetanib in patients with 
metastatic hereditary forms of MTC. Confirmed partial response was reported in 17% of 
patients, where another 53% had stable disease lasting at least 24 weeks.[66] A second 
phase II trial in advanced hereditary MTC by Robinson et al. showed a partial response 
rate of 16% and stable disease 24 weeks or longer in 53% of patients.[67] Results of a 
randomized placebo controlled multicenter phase III trial in 331 patients with locally 
advanced or metastatic MTC showed an objective response in 43% of patients, all which 
were durable. Median PFS was 30 months in the vandetanib group and 19 months 
in the placebo group (p<0.001). The OS did not significantly differ between the two 
groups.[68] Vandetanib has a registration for metastatic medullary thyroid carcinoma.
 Sorafenib (BAY 43-9006) is an orally active TKI targeting BRAF, VEGFR 1 and 2 
and RET, conducting pro-apoptotic and anti-angiogenic actions. Several phase II studies 
with Sorafenib in patient with advanced DTC have been conducted, showed promising 
results.[69-72] In the Phase III DECISION trial, investigating the efficacy and safety of 
sorafenib in patients with advanced, RAI-refractory DTC, 417 patients were randomised 
between sorafenib twice daily 200 mg and placebo with the option of crossover in 
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case of disease progression. The median progression-free survival in the placebo and 
sorafenib group was 5.8 months and 10.8 months respectively (HR 0.587; p < 0.0001).
[73] In a small pilot study in patients with metastatic MTC, responses were described 
in 40% of the patients.[74] Lam et al performed a phase II trial in which the efficacy 
of sorafenib in hereditary (arm A) and sporadic (arm B) metastatic MTC patients was 
examined. They included 16 patients with sporadic MTC. One patient had a PR (6.3%) 
and 14 patients had stable disease (87.5%). Median PFS was 17.9 months. Arm A was 
prematurely terminated because of slow accrual.[75] Sorafenib has a registration for 
DTC.
 Sunitinib (SU11248) is an oral TKI of VEGFR 1-3, RET, and RET/PTC subtypes 1 
and 3. Results of a phase II trial in patients with MTC (n=25) showed a PR in 8 (32%) and 
SD in 13 (52%) patients.[76] Another phase II trial in 28 DTC and 7 MTC patients reported 
a CR in 3%, a PR in 28% and SD in 46% of all patients combined. Median PFS was 12.8 
months.[77] Recent data of a phase II trial in 11 patients with DTC demonstrated a CR in 
9%, a PR in 18% and SD in 45% of patients with the median PFS being 11.2 months.[78]. 
Sunitinib does not have a registration for thyroid cancer.
 Imatinib (STI571) is an oral TKI of BCR-ABL and c-KIT. Its function is based on 
its inhibition of RET autophosphorylation and RET mediated cell growth. So far, two 
small phase II trials that studied the efficacy of imatinib in patients with metastatic MTC 
have been completed. In both trials no response was confirmed and only a few patients 
achieved stable disease.[79,80] Furthermore, a phase I trial with MTC patients treated 
with imatinib combined with dacarbazine and capecitabine did not report objective 
responses.[81]
Pazopanib (GW786034) is an orally bioavailable TKI that targets VEGFR 1-3 and 
c-KIT. Its antitumor activity in advanced and progressive DTC was demonstrated in a 
phase II trial with 39 patients. Partial responses were confirmed in 49% of patients. 
Median PFS was 12 months.[82]. Pazopanib has not been registered for thyroid cancer.
 Cabozantinib (XL184) is an oral inhibitor of RET, c-MET and VEGFR 1 and 2. 
C-MET activation triggers tumor growth and angiogenesis. Moreover, in patients with 
PTC and MTC overexpression and frequent mutations of the c-MET receptor have been 
reported.[42] A phase I trial examined the efficacy of cabozantinib in patients with 
advanced malignancies, including patients with MTC. In MTC patients with measurable 
disease, 29% had a confirmed PR and 68% had either confirmed PR or prolonged stable 
disease ≥ 6 months.[83] A randomized placebo controlled phase III trial (EXAM) was 
conducted in patients with advanced or metastasized MTC. Median PFS was 11 months 
in the cabozantinib group and 4 months in the placebo group (p<0.001) with an overall 
RR of 28% and OS HR of 0.83. Remarkable was the significant longer PFS in patients 
harboring a RET mutation (60 vs. 20 weeks).[84] Cabozantinib is now registered for the 
treatment of advanced MTC. The possible role of cabozantinib in patients with DTC is 
currently being investigated in a phase II clinical trial (NCT02041260). Cabozantinib has 
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a registration for locally advanced and metastatic medullary thyroid carcinoma.
 Vemurafenib (PLX 4032) is an orally administered small molecule that specifically 
inhibits only the V600E mutant BRAF kinase, without appreciable impairment of wild-
type BRAF protein or other RAF kinases. Three patients with PTC and documented 
V600E BRAF mutations have been treated in a phase I study, with 1 of the 3 experiencing 
a partial response and the other 2 having prolonged stable disease.[85] Data from a 
phase II clinical trial in patients with PTC showed a PR in 38% of patients not previously 
treated with a TKI and in 26% of patients previously treated with a TKI. The median PFS 
was 16 and 7 months respectively.[86]. Vemurafenib does not have a registration for 
thyroid cancer.
 Lenvatinib (E7080) is also an inhibitor of multiple TKs, especially VEGFR’s, 
c-KIT, PDGFR beta stem cell factor receptor, RET and FGFR1-4.[87-89] Based on the 
encouraging results of a phase II clinical study with lenvatinib in patients with RAI 
refractory DTC, the placebo controlled phase III SELECT trial was conducted (lenvatinib 
n=261, placebo n=131). The RR was 64% (4 CRs and 165 PRs) in the lenvatinib group and 
1.5% in the placebo group (p<0.001). Median PFS was 18 and 4 months respectively. 
Median OS was not reached in both groups.[90,91]. Lenvantinib has been registered for 
locally advanced and metastatic DTC.
 Selumetinib is a non-ATP competitive MAPK kinase inhibitor (MEK1/2). A phase 
2 study of selumetinib in 39 PTC patients reported a PR in 3% and SD in 54% of the 
32 evaluable patients with a median PFS of 8 months in patients harboring a BRAF 
mutation and 3 months in patients without a BRAF mutation.[92] More recent data of a 
phase II trial in patients with metastasized DTC (n=20) showed a PR and SD in 25% and 
15% respectively. Remarkable was the enhanced RAI uptake and tumor reduction in 
patients with a NRAS mutated tumor.[93] This drug is still under investigation.
 Everolimus (RAD001) is an orally available derivative of rapamycin that interferes 
with the regulation of cell cycling, cell growth and cell survival mechanisms through 
binding to the mammalian target of rapamycin.[43] A phase II study of everolimus 
in patients with advanced thyroid cancer of all histologic subtypes (n = 38), reported 
a partial response (PR) and durable stable disease (SD) in 5% and 45% of patients, 
respectively. The median PFS (mPFS) was 47 weeks.[94] Another study of everolimus 
in DTC (n = 31) showed 1 (3%) patient with a PR and 18 (58%) with durable SD. PFS was 
16 months, and 1-year survival was 76%.[95] Recently published results of a phase II 
trial in patients with advanced DTC reported SD in 17 (65%) patients, of which 15 (58%) 
showed SD >24 weeks. Median PFS and OS were 9 and 18 months, respectively.[96] 
Wagle et al. showed 1 patient diagnosed with ATC derived from FTC-OV with striking 
response upon giving everolimus due to a homozygous somatic TSC1 variant. This 
patient showed relapse when the tumor was selected for a secondary somatic MTOR 
variant.[97] Everolimus does not have a registration for thyroid cancer.
 Crizotinib is an inhibitor of ALK, MET and ROS1 and is approved for the 
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treatment of patients with ALK- or ROS-positive advanced non-small-cell lung cancer 
(NSCLC). A study with crizotinib in patient with ALK-positive malignancies (excluding 
NSCLC) showed a PR lasting 14 weeks in a patient with advanced MTC.[98] Godbert et 
al. reported an exceptional response in a patient with ALK-rearranged ATC and lung 
metastases. Over 90% of all pulmonary lesions responded to crizotinib treatment and 
this response was still ongoing after 6 months.[99] 
IMMUNOTHERAPY
Despite the low mutational load of most thyroid cancers, which would theoretically 
indicate a lack of potential benefit upon giving immunotherapy, targets were 
investigated. Several reports demonstrated higher programmed death-ligand 1(PD-
L1) expression in thyroid tumors. Furthermore, PD-L1 levels were higher in advanced 
tumors and more frequently expressed in ATC, suggesting that PD-L1 expression is 
a late event in thyroid carcinogenesis.[100-102] In addition, it was demonstrated that 
BRAF V600E mutated PTCs frequently express PD-L1. These findings show that BRAF 
V600E can induce promotion of tumor immune escape mechanisms, may contribute to 
the aggressive tumor behavior of BRAF V600E mutated tumors.[103]
Preliminary results of a study with pembrolizumab in patients with advanced 
PTC or FTC, who failed standard treatment and showed PD-L1 expression, reported a 
PR in 2 out of 22 patients (9%). SD was seen in 55% of patients, PFS and OS at 6 months 
were 59% and 100% respectively.[104] Kollipara et al. reported an exceptional response 
in 1 patient with a BRAF and PD-L1 positive recurrent ATC, treated with vemurafenib and 
nivolumab. After 20 months the patient continues to be in complete radiographic and 
clinical remission.[105]  Multiple clinical trials evaluating immune checkpoint inhibitors 
in patients with thyroid cancer are ongoing (https://clinicaltrials.gov).
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Table 2: Summary of studies in thyroid cancer




inhibitors DTC 18 0# 24 % (>24 wks)# 16 wks # Pennell et al. 2008
Gefitinib MTC 4 <12 wks
ATC 5 16 wks #
AZD6244 DTC 39 3% 66% 32 wks Lucas et al. 2010
MTC 2 - 100% (>20 wks) - Banerji et al. 2010
Multikinase
inhibitors
Axitinib All types 5 0% - - Rugo et al. 2005
DTC 45 31% 42% 18mnths# Cohen et al. 2008
MTC 11 18% 27%
DTC 52 35% 35% 27 mnths Locati et al. 2014
Motesanib DTC+MTC 71 7% 49% (>12 wks) - Rosen et al. 2007
DTC 93 14% 35% (>24 wks) 40 wks Sherman et al. 2008
MTC 91 2% 28% (>24 wks) 48 wks Schlumberger et al. 2009
Vandetanib DTC 145 8% 57% 11 mnths Leboulleux et al. 2012
MTC 30 20% 53% 28 mnths Wells et al. 2010
MTC 19 16% 53% 6 mnths Robinson et al. 2010
MTC 231 45% 42% - Wells et al. 2012
MTC 60 20% 55% 16 mnths Chougnet et al. 2015
Sorafenib DTC 41 15% 56% (≥24 wks) 15 mnths Kloos et al. 2009
30 23% 79 wks Gupta et al. 2008
26 27% 18 mnths Schneider et al. 2012
207 12% 42% (≥26 wks) 11 mnths Brose et al. 2013
MTC 16 6% 88% 18 mnths Lam et al. 2010
Sunitinib All types 17 6% 80% - Ravaud et al. 2009
DTC+MTC 43 13% 68% - Cohen et al. 2009
DTC+MTC 35 31% 46% 13 mnths Carr et al. 2010
MTC 35 35% 57% 7 mnths De Souza et al. 2010
Imatinib DTC+MTC - - - - -
Pazopanib DTC 37 32% 65% 12 mnths Bible et al. 2009
Cabozantinib MTC 33 28% - 11 mnths Kurzrock et al. 2011
Vemurafenib DTC 3 33% 66% 12 mnths Kim et al. 2013
DTC 51 38%+ - 16 mnths+ Brose et al. 2013
26%+ 7 mnths+
Lenvatinib DTC 58 50% 28% 13 mnths Sherman et al. 2011
DTC 261 65% - 18 mnths Schlumberger et al. 2015
Selumetinib DTC 32 3% 54% 8 mnths Hayes et al. 2012
DTC 20 25% 15% - Ho et al. 2013
Everolimus All types 38 5% 45% 12 mnths Lim et al. 2013
MTC 7 - 57% 8 mnths Schneider et al. 2015
DTC 28 - 65% 9 mnths Schneider et al. 2017
# overall outcomes, RR response rate, SD stable disease, PFS progression free survival, 
DTC differentiated thyroid cancer, MTC medullary thyroid cancer, wks weeks, mnths months, - 
not reported, + in the TKI naive group and in the group previously treated with a TKI respectively
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The large development in the treatment of advanced thyroid cancer is due to the 
unraveling of the carcinogenesis of thyroid cancer. Aberrations in RET/PTC-RAS-RAF-
MAPK pathways are present in a high percentage of thyroid cancer, and there are also 
angiogenesis switch alterations and involvement of other receptor tyrosine kinases, 
such as EGFR or c-Met. Because of the oncogenic roles of activated BRAF, RET, and 
RET/PTC kinases, and RET/PTC kinases, the assumption was that specific targeting of 
these kinases could block tumor growth and induce senescence.[106] As can be shown 
from multiple clinical trials in thyroid cancer, these assumptions have appeared to be 
correct. Several promising agents have been found in DTC and MTC (table 2). However, 
the search for new agents in sequential or combination therapy will still be necessary, 
since patients eventually become progressive on these agents or do not tolerate them.
OUTLINE OF THIS THESIS
In this thesis, clinical aspects of advanced thyroid cancer were studied. The first part 
of this thesis is focused on the role of sorafenib in the treatment of patients with 
advanced thyroid cancer. Chapter 2 describes the long-term results of a prospective 
phase II clinical trial to determine the efficacy of sorafenib in patients with advanced 
radio-iodine refractory differentiated thyroid cancer. Drugs such as sorafenib may 
induce metaplasia/clonal divergence of metastatic thyroid cancer and cause diagnostic 
misclassification. Furthermore, Sorafenib is potentially involved in the tumorigenesis of 
secondary non-cutaneous SCC. In Chapter 3 we describe three patients with a history of 
sorafenib treatment for advanced radioactive iodine refractory papillary thyroid cancer 
who presented with secondary non-cutaneous lesions.
In the second part we report the outcomes of clinical trials with everolimus in patients 
with advanced thyroid cancer. In Chapter 4 we report the results of a prospective phase 
II study on the safety and efficacy of everolimus in patients with advanced MTC. Chapter 
5 evaluates the correlation between everolimus exposure and toxicity and its population 
pharmacokinetics in patients with advanced thyroid cancer of all histological subtypes. 
In Chapter 6 the results of a prospective phase II clinical trial to determine the efficacy 
and safety of everolimus in patients with advanced follicular-derived thyroid cancer are 
presented.
 This thesis and future prospective are discussed in Chapter 7. A summary of 
this thesis is given in Chapter 8 in English and in Chapter 9 in Dutch.
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Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine 
refractory differentiated thyroid carcinoma: final results of a phase II trial
ABSTRACT
Objective
We conducted a prospective phase II clinical trial to determine the efficacy of sorafenib 
in patients with advanced radio-iodine refractory differentiated thyroid cancer. In this 
article, the long-term results are presented.
Patients and methods
Thirty-one patients with progressive metastatic or locally advanced radioactive iodine 
refractory differentiated thyroid cancer received sorafenib 400 mg orally twice daily. 
The study end points included response rate, progression-free survival (PFS), overall 
survival (OS), best response by Response Evaluation Criteria in Solid Tumors criteria 
1.0, and toxicity.
Results
Median PFS was 18 months (95% confidence interval (95% CI): 7–29 months) and 
median OS was 34.5 months (95% CI: 19–50 months). Eight patients (31%) achieved a 
partial response and 11 patients (42%) showed stable disease after a median follow-up 
of 25 months (range 3.5–39 months). Toxicity mostly included hand foot syndrome, 
weight loss, diarrhea, and rash.
Conclusion 
Sorafenib has clinically relevant antitumor activity in patients with progressive 
metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer. 
Sorafenib can nowadays be considered as the standard option in these patients.
Key words 
long term outcomes, phase II trial, sorafenib, thyroid cancer
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Thyroid cancer is the most prevalent endocrine malignancy, accounting for 95% of cancers of 
the endocrine system and 66% of endocrine cancer mortality in 2010 [1]. The current incidence 
in Europe is 49/1 000 000 per year, with a nearly three times higher incidence in women [2]. 
 Differentiated thyroid carcinoma (DTC) is by far the most common (95%) 
subtype, and includes papillary (PTC, 80%) and follicular (FTC, 10-15%) as well as 
subtypes like Hurthle cell carcinomas. The majority of DTCs are slowly progressive, 
and, when identified at an early stage, frequently cured with adequate surgical 
management and radioactive iodine 131-I ablation (RAI) therapy. However, metastatic 
DTC that has become inoperable or refractory to RAI therapy is associated with a 
less favorable prognosis, as 10-year survival varies between 25% to 40%[3,4]. The 
efficacy of conventional chemotherapy in DTC is negligible, and chemotherapy 
is therefore no longer recommended in international guidelines [5,6]. As a result 
of increased understanding of thyroid tumorigenesis, potential targets and novel 
therapeutic agents that target biological abnormalities have been identified. 
 In DTC, the role of activated genetic aberrations in the RET-RAS-RAF-MAPK 
signaling pathway in tumor development and progression has been determined. The 
B-type Raf kinase (BRAF) V600E mutation has been reported in 29-69% of PTC and 
is associated with recurrent and persistent disease with a higher rate of lymph node 
metastasis and higher TNM stage [7,8]. In a review of 11 studies in thyroid cancer, up 
to 50% of follicular and 12% of Hurthle cell malignancies harbored RAS mutations or 
RAS-downstream signaling, PIK3CA, mutations [9]. Rearrangements in the RET proto-
oncogene occur in up to 25% of PTC, resulting in the generation of chimeric oncogenes 
responsible for the initiation of tumor formation [10]. Additionally, RAS mutations and 
RET/PTC translocations also result in aberrant signaling through BRAF. Furthermore, the 
RET–RAS–RAF pathway leads to vascular endothelial growth factor (VEGF) and VEGF 
receptor (VEGFR) synthesis through interconnection with the epithelial growth factor 
receptor (EFGR) activated cascade [11]. In turn, these are the most important regulators 
in the proces of angiogenesis. Increased vascularity plays a crucial role in tumor growth 
and generating metastasis [12]. In human thyroid cancer, VEGF over expression is 
associated with increased tumor stage and invasiveness [11]. Pazopanib is a TKI that 
targets VEGFR 1–3 and c-KIT. Its antitumor activity in advanced and progressive DTC 
was demonstrated in a phase II trial, which showed a partial response (PR) rate in 49% 
of patients (n=39). Median progression free survival(PFS) was 12 months [13,14]. XL184 
(cabozantinib) is an oral inhibitor of RET, c-MET and VEGFR 1 and 2. c-MET activation 
triggers tumor growth and angiogenesis. Moreover, in patients with PTC and MTC, 
overexpression and frequent mutations of the c-MET receptor have been reported [15]. 
Antitumor activity of cabozantinib in patients with DTC was recently reported at the 
524722-L-bw-Schneider
Processed on: 9-10-2018 PDF page: 32
32
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine 
refractory differentiated thyroid carcinoma: final results of a phase II trial
2012 ASCO Annual Meeting. Cabanillas et al. found confirmed PR and stable disease 
(SD) in 53 and 40% of patients respectively (n=15). Disease control rate (PR + SD) was 
80% at 16 weeks. At the time of data presentation, median PFS and overall survival (OS) 
had not been reached [16].
E7080 (lenvatinib) is also an inhibitor of multiple TK, especially VEGFRs, c-KIT, platelet-
derived growth factor receptor beta stem cell factor receptor. In animal studies, it 
has been shown to have potent antitumor activity against small cell lung cancer and 
breast cancer most likely through inhibition of VEGFR-2 and VEGFR-3 [17,18]. A phase 
II trial of lenvatinib in RAI refractory DTC (n=58) by Sherman et al. showed a PR rate 
of 50% and a median PFS of 13 months [19]. A recent study by Rajoria et al. showed 
estrogen to be a key regulating factor of VEGF expression in thyroid cells, suggesting 
a role for anti-estrogens in the therapeutic regimen to treat thyroid cancer [20]. 
 As a result of this increased understanding of the biological basis for thyroid 
cancer development, multiple clinical trials with multi-target tyrosine kinase inhibitors 
(TKIs) have been conducted. Sorafenib (BAY 43-9006) is an orally active TKI that 
targets BRAF, VEGFR 1 and 2 and RET, implementing antiangiogenic and proapoptotic 
actions. Results of an update of a phase II study on sorafenib, reported at the 2011 
ASCO Annual Meeting by Brose et al., showed a PFS of 24 months and an OS of 35 
months in 47 patients with DTC and poorly differentiated thyroid cancer (PD)(n=55). 
A PR was achieved in 38% of patients and 47% had SD [21]. An other phase II study 
in mainly patients with advanced DTC (n=30), reported a PR rate of 23%, a SD rate 
of 53% and a median PFS of 20 months [22]. Kloos et al. examined the effect of 
sorafenib mainly in patients with metastatic PTC (n=41) and reported a PR and SD of 
15% and 56% respectively. The median PFS was 15 months [23]. Recent results of a 
study with the MEK 1/2 inhibitor selumetinib showed reinduction of radio iodine 
uptake in 60% of patients with RAI refractory thyroid cancers of follicular origin [24]. 
 Our phase II study was designed to assess the effects of sorafenib on 
restoring the susceptibility to RAI therapy, tumor progression and safety in RAI 
refractory DTC. The first report of this study by Hoftijzer et al. showed a promising 
efficacy and tolerability of sorafenib, but no beneficial effects on radioiodine 
uptake [25]. Here, we report the long term outcomes of this sorafenib trial in 




Details of study design and patient eligibility of this study have been described 
previously [25]. Briefly, eligibility criteria were the presence of progressive metastases 
or unresectable local recurrence of DTC for which RAI therapy was no longer effective, 
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as indicated by prior negative post-therapeutic whole body scintigraphy (WBS). 
Progressive disease was defined according to Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria 1.0 12 months before initiation of treatment. Patients had 
undergone total thyroidectomy and RAI ablative therapy. Eastern Cooperative Oncology 
Group performance status had to be less than 2 and life expectancy had to be more than 
3 months. Written informed consent was provided by all patients before enrollment 
onto the trial. The study protocol was approved by the Institutional Review Board of 




We performed a non-randomized, open-arm, phase II trial of sorafenib in 31 patients 
with advanced RAI refractory DTC. For complete description of study design we refer 
to the paper of Hoftijzer et al.[25]. Primary objective of this study was determination 
of the efficacy of sorafenib treatment with a partial response as the primary endpoint. 
The secondary objective was to study RAI re-uptake and the safety of sorafenib as an 
anti-tumor drug for advanced RAI refractory DTC patients. Sorafenib was administered 
at a dose of 400 mg orally twice a day until disease progression, uncontrollable side 
effects, death or patients own request. Safety assessments consisted of physical 
examination, documentation of adverse events and laboratory parameters (total blood 
count, electrolytes, kidney and liver function) and were performed every 4 weeks. The 
incidence, grade and relationship of adverse events to the drug were graded with the 
use of Common Terminology Criteria for Adverse Events (version 3.0). 
 After completion of 6 months treatment, patients were allowed to continue 
sorafenib treatment when a favorable response (complete remission, partial remission, 
or stable disease) had been achieved. Sorafenib was thereafter continued until 
progression according to RECIST 1.0 criteria with CT scanning performed every 6 
months. 
In this article, we report the long term outcomes and tolerability of sorafenib in 
patients with advanced RAI refractory DTC. 
 
Statistical methods
In this study, data are reported as median ± SD, median (range) or proportions. 
Best objective response rate refers to the proportion of patients who had the best 
response rating for CR or PR according to RECIST 1.0. The OS, PFS (defined as the 
time from starting study drug to progression) and overall disease control rate with 
associated 95% CIs, were obtained using the Kaplan-Meier method. Adverse events 
were scored according to the National Cancer Institute’s Common Terminology 
Criteria for Adverse Events (CTCAE), version 3.0. Other safety parameters, including 
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laboratory data, were summarized descriptively. Variables possibly influencing 
response to sorafenib were analyzed with binomial logistic regression. The 
calculations were performed using SPSS 17.0 for Windows (SPSS, Chicago, IL, USA). 
RESULTS
Patient characteristics
All 31 patients were included in this long term outcomes study on sorafenib. The follow-
up of the study ended on 1 March 2011 with 5 patients excluded from the efficacy 
analysis because they did not reach the first radiological evaluation at 6 months. One 
patient requested to stop sorafenib treatment after 4 days, 1 patient developed small 
cell lung cancer and 3 patients discontinued treatment because of adverse events. 
Median follow-up period was 25 months (range 3.5- 39 months) and median sorafenib 
treatment period was 9.2 months (range 0.1-39 months). By the time the follow-up of 
the study ended (March 2011), 4 patients (15.4%) were still on sorafenib (Figure 1). 
 Baseline characteristics of the included patients are listed in Table 1. As can be 
expected, Hurthle cell metaplasia, which is associated with poor RAI responsiveness, 
was overrepresented in the patient group (42%). Two of 13 PTC patients had a poorly 
differentiated carcinoma. A total of 15 mutations were identified on primary tumor 
material, of which BRAF V600E was most frequently observed with 10/13 PTC patients 
harboring a BRAF V600E mutation.
Figure 1 Study flowchart
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Age (year) (median, range) 64 (53-82)
Time from diagnosis (year) (median, range) 3.9 (0.3-18)
Histology (No.; %)
Papillary
   Tall cell
   Hurthle cell metaplasia
   Poorly differentiated
Follicular variant papillary
Follicular










Initial TNM stage (No.; %)
IB (T2N0M0)
IIB (T2-3 N0-1 M0)
IIIA (T1-3 N1-2 M0)







Tumor extent at study entry (No.; %)
Thyroid bed only 
Lungs only
Lungs and bone only



















* Including both thyroid bed (n=5) and neck lymph nodes (n=4)
Efficacy
Of the 31 patients enrolled in this study, 26 patients were eligible for efficacy analysis. 
Five patients were excluded for the reasons previously mentioned. Data on efficacy are 
given in Table 2 and Figure 2. 
 At a median follow-up 25 months, the overall disease control rate was 27%. The 
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total proportion of PR was 31% (n=8), which were all achieved in the first 6 months of 
treatment. Four patients (15%) had an ongoing partial response (PR) and 3 patients (12%) 
showed ongoing stable disease (SD). There were no complete responses. Individual 
data per patient response is summarized in Table 3. At the time of this data analysis, 
the cumulative number of patients with progressive disease was 15 (58%). Disease 
progression was not influenced by age, gender or histology, including the presence of 
Hurthle cell metaplasia. Furthermore, the presence of a BRAF V600E mutation was not 
related to disease progression. The prevalence of other mutations was too low to allow 
statistical analysis. Disease progression in soft-tissue metastases or bone metastases 
dit not significantly differ. However, the favorable responses seen in 3 patients with bone 
metastases were all based on regression of metastases other than bone, predominantly 
lung, whereas the bone metastases were stable. The overall median OS was 34.5 
months (95% CI: 19-50 months). In the presence of bone metastases, median OS was 
significantly worse with 23 months (95% CI: 20-26 months) as compared to the median 
OS of the whole group. However, at the time of this data analysis, median OS was 
not reached for patients without bone metastases (Figure 2A).  Age and gender did 
not influence OS. Estimation of median PFS was 18 months (95% CI: 7-29 months). 
Similarly, the median PFS was influenced by the presence of bone metastases. Median 
PFS was 20 and 12 months in the absence and presence of bone metastases respectively 
(Figure 2B). A relation between OS and PFS and site of bone metastases could not be 
established since 12 of 13 patients with bone metastases had metastases localized in the 
axial skeleton. Hurthle cell metaplasia and reduction of drug-dose did not influence PFS. 
 Thyroglobulin (Tg) response reflected the radiological response (Table 4). 
From baseline, patients with a PR had a median decrease of 24 µg/l (range -2746-
2.6 µg/l) in their serum Tg levels. Patients with SD showed a median elevation 
of 19 µg/l (range -60- 3724 µg/l). The serum Tg levels in patients that showed PD 
increased by a median of 49 µg/l (range -5320- 87736 µg/l). The 54-year-old woman 
with pulmonary metastases of a Hurthle cell FTC reported at 6 months with high Tg 
levels (99900 µg/l) but a decrease in number, size and density of all metastases, died 
2 months later from disease progression with a remained high Tg level (89400µg/l). 
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Table 3 Efficacy analysis 
Parameter
Number of patients (% of total)
Total patients 31
Assessable patients 26
Median duration of treatment (months; range) 15 (0.1-39)
Median duration of follow up (months; range) 25 (3.5-39)
Best response by RECIST 1.0
   Complete response
   Partial response
   Stable disease





Overall disease control 7 (27)
Median duration of SD (months; range) 26.5 (3-38)
Median overall response duration (months; range) 29.6 (3-33)
Median PFS (95% CI)
   With BM




Median OS (95% CI)
   With BM




RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, PFS 
progression free survival, OS overall survival, BM bone metastases, NR not reached 
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Figure 2 Kaplan–Meier curves of (A) overall survival (OS) and (B) median progression-free survival 
(PFS)
A: Kaplan-Meier estimate of overall survival (OS). Overall median OS was 34.5 months. In the 
presence of bone metastases, median OS was 23 months At the time of this data analysis, median 
OS was not reached for patients without bone metastases.
B: Kaplan-Meier estimate of progression free survival (PFS). Estimation of median PFS was 18 
months. Median PFS was 20 months in the absence and 12 months in the presence of bone 
metastases.
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Duration of response 
(months)
PR Papillary IB 33 *
PR
Follicular with Hurthle cell 
metaplasia
IIB 33 *
PR Papillary IIB 33 *
PR Papillary IV 30
PR Follicular IIB 24
PR Follicular IIB 24
PR Papillary IIB 18 *
PR Papillary IIIA 6
SD Papillary IIIA 38
SD Follicular IIB 36
SD
Follicular with Hurthle cell 
metaplasia
IIB 12
PR partial response, SD stable disease, IB (T2N0M0), IIB (T2-3 N0-1 M0), IV (any T any N M1), IIIA 
(T1-3 N1-2 M0), * ongoing response
Table 4 Thyroglobulin response per patient response
RECIST 1.0 CR PR SD PD
Baseline serum Tg levels 
(median; range)
Non 50 (4.5-3126) 41 (2-1817) 382 (26.5-8570)
Last serum Tg levels 
(median; range)
Non 19 (0.9-1894) 94 (14-4140) 373 (38-89400)






RECIST Response Evaluation Criteria in Solid Tumors Tg thyroglobulin, CR complete response, PR 
partial response, SD stable disease,  PD progressive disease
Treatment tolerability and adverse events
Eighteen patients (58%) required dose reduction due to toxicity. Four of them (13%) 
discontinued the study later on due to adverse events (AEs).Of these, 3 patients 
suffered from a myocardial infarction after respectively 1, 20 and 22 months of 
sorafenib treatment and one patient quitted due to complaints of malaise after 
39 months. Fourty-four percent of dose reductions occurred in the first month of 
treatment. Further details on dose reduction and daily sorafenib dose are listed in 
Table 5. In total, 7 patients (23%) terminated study participation as a result of drug-
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related AEs. There were 3 patients who discontinued sorafenib before dose reduction 
after 1, 12 and 19 months due to angioedema, congestive heart disease, and malaise 
and weight loss, respectively. One patient discontinued treatment after 3 months 
due to the development of small cell lung cancer. One patient was diagnosed with 
carcinoma of the tongue after 46 months of sorafenib treatment. Thirteen patients 
(42%) required levothyroxin dose adjustments in order to maintain euthyroidism. 
 All observed AEs are listed in Table 6. Treatment-related AEs were 
predominantly of grade 1 or 2, with the most common events including hand foot 
syndrome (HFS), weight loss, diarrhoea and rash. Grade 3 AEs consisted of HFS 
(23%), weight loss (10%), diarrhoea (6%), rash (16%), mucositis (10%) and congestive 
heart disease (3%). Grade 4 AEs comprised myocardial infarction in 3 patients (10%), 
which led to death within 2 months after the infarction in one patient. The majority 
of AEs were seen in the first year of treatment and were controllable with either dose 
reduction, medication or supporting measures (f.e. dietary consultation and additional 
feeding). No correlations were found between toxicity and performance state or age. 
Table 5 Daily sorafenib dose and dose reduction
3 months 6 months 12 months
Dose reduction (No.; %) 13 (42) 16 (52) 18 (58)
Daily sorafenib dose (mg)
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Table 6 Adverse events
                                                          All





(% of total (n=31))    
1 2 3  4
Hand foot syndrome 22 (71) 8 (36) 7 (32) 7 (32)
Weight loss 18 (58) 7 (39) 10 (56) 3 (17)
Diarrhoea 16 (52) 5 (31) 9 (56) 2 (13)
Rash 17 (55) 11 (65) 1 (6) 5 (29)
Alopecia 16 (52) 14 (88) 2 (12)
Mucositis 15 (48) 11 (73) 1 (7) 3 (20)
Hypocalciemia 15 (48) 14 (93) 1 (7)
Hypertension 13 (42) 4 (31) 4 (31) 5 (38)
Hypophosphatemia 11 (35) 11 (100)
Anemia 11 (35) 11 (100)
Hypoparathyroidism 10 (32) 10 (100)
Thrombopenia 9 (29) 9 (100)
Hypothyroidism 8 (26) 8 (100)
Leukopenia 7 (23) 7 (100)
Nausea 3 (10) 3 (100)
Myocardial infarction 3 (10) 3 (100)
Congestive heart disease 1 (3) 1 (100)
Hematuria 1 (3) 1 (100)
Deep venous thrombose 1 (3) 1 (100)
Hyponatriemia 1 (3) 1 (100)
Pneumothorax 1 (3) 1 (100)
Small cell lung cancer 1 (3) 1 (100)
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DISCUSSION
 
The developments in the treatment of advanced thyroid cancer are a result of increased 
understanding of thyroid tumorigenesis. A high percentage of differentiated thyroid 
cancers contain aberrations in the RET/PTC-RAS-RAF-MAPK pathway. In addition, 
the RET–RAS–RAF pathway leads to VEGF and VEGFR synthesis through the EFGR 
activated cascade. Hence, compounds targeting the activated RET–RAS–RAF pathway 
and beyond, anti angiogenic compounds or a combination of both, may be effective in 
RAI non-avid DTC [26]. Several clinical trials in thyroid cancer have shown considerable 
percentages of clinical responses, suggesting this assumption to be accurate. Of the 
targeted therapies that have shown promising results in advanced  differentiated thyroid 
cancer, only sorafenib targets both BRAF and RET, as well as VEGFR. However, sorafenib 
is a relatively weak BRAF inhibitor. The most potent BRAF inhibitor, vemurafenib, 
might be more effective in PTC harboring a BRAF mutation and is currently under 
study in an international phase II trials (www.clinicaltrials.gov, NCT01286753) [27]. 
 Our study is the first study reporting the long term effects of sorafenib 
treatment in advanced RAI refractory DTC patients. We also provided results of the 
influence of bone metastases on survival outcome and PFS. Our results were not 
influenced by subtypes of thyroid cancer, since we only included patients with DTC, 
ensuring a homogeneous study population. In our trial we observed beneficial effects 
of sorafenib. At 6 and 25 months, median PFS was 14.5 and 18 months respectively. 
At 6 and 25 months, median OS was 25 months and 34.5 months respectively. The 
PR rate of 25% we observed in the first 6 months of the trial is one of the highest 
PR rates reported in sorafenib trials in DTC. Kloos et al. found a PR rate of 15% in 
patients with metastatic PTC [23]. Gupta et al. reported a PR of 23% (DTC, MTC and 
ATC) whereas Ahmed et al. observed a PR in 21% of patients with metastatic thyroid 
cancer (DTC and MTC) [22,28]. Our high PR rate could be attributed to the differences 
in patient categories (histologies, tumor stages, sites of metastases and tumor 
extent), study design and analytical methods between the different phase II trials. 
 The explanation for the significant less favorable outcome in patients with 
bone metastases remains unclear. The relationship between the genetic profile of bone 
metastases and responsiveness to sorafenib is hard to establish given the lower tissue 
levels and difficulties in obtaining tissue from bone metastases. It can be hypothesized 
that VEGFR targeted therapies are less effective in bone metastases since the role of 
VEGFR signal transduction in tumor expansion may differ between soft tissue and bone 
metastases. Another explanation may be that through systemic release of cytokines or 
proteins from the bone microenvironment the presence of bone metastases influences 
the response to sorafenib in soft-tissue metastases.    The dose of sorafenib 
used in our study was generally well tolerated, although dose reductions were required 
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in 58% of patients. Tumor response however, was not affected by dose reductions. 
Toxicities observed in our study were mostly grade 1-2 and similar to those reported in the 
other phase II trials of sorafenib [21-23,28,29]. A long term safety evaluation of sorafenib 
in advanced renal cell carcinoma showed similar results, supporting our findings [30]. 
Dermatologic adverse events were the most commonly observed. A recent study of 
sorafenib in patients with hepatocellular carcinoma reported better response in patients 
with early skin reactions [31], however, we were not able to establish that correlation. 
Adverse effects were in the majority of cases manageable with dose reduction, medication 
or supplementary measures. However, beneficial effects on tumor response should 
always be weighed against the side-effects and quality of life of targeted therapies [3,4,29]. 
 There are some issues that have to be addressed to. RECIST criteria should 
be applied for judgement of progression for inclusion in trials and for follow-
up scans to determine treatment effect. However, RECIST criteria have several 
limitations for the determination of efficacy of targeted drug activity. This is shown 
by the fact that in our study, some of the patients with PD based on new lesions had 
stable or even reduction in the target lesion’s longest diameter. Nevertheless, the 
RECIST criteria are the best criteria to date and should be used in every clinical trial. 
 Another issue is that in studies of targeted therapy in advanced thyroid cancer, 
a substantial proportion of patients (33%-50%) had stable disease of varying duration 
as best response [32]. Given the indolent natural history of these tumors, stable disease 
may be considered to be of limited value. Considering this, the determination of the best 
primary end point stays an issue. Objective response rates do not correlate per se with 
OS. Given the indolent nature of advanced thyroid cancer, progression-free survival or OS 
are not always preffered primary end points. Therefore, only patients with documented 
progressive disease should be included in clinical trials, permitting a smaller sample 
size and a shorter time for follow-up to demonstrate a difference in response to therapy 
between treatment groups. In addition, sorafenib treatment should only be initiated in 
patients with progressive disease or significant tumor burden in the presence of RECIST 
targets. Furthermore, patients with stable disease at baseline may not benefit from 
therapy and do not need treatment with targeted agents, with all possible side-effects. 
 In conclusion, sorafenib is generally well tolerated and has demonstrated to be 
clinically active in the long term in advanced RAI refractory DTC. In order to enhance 
sorafenib treatment efficacy, further trials need to focus on sequential or combination 
therapy, since patients eventually become progressive on sorafenib or do not tolerate 
it. More trials with new targeted agents are under way and the outcomes of these trials 
will contribute to a better treatment and understanding of advanced thyroid cancer.
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ABSTRACT
Background
Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets 
B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, 
and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic 
actions in a wide range of solid tumors. A side effect of sorafenib is the occurrence of 
cutaneous squamous tumors. 
Case presentation
Here we describe three patients with a history of sorafenib treatment for advanced 
radioactive iodine refractory papillary thyroid cancer (two with a BRAF c.1799 T>A and 
one carrying a rare c.1799-1801het_delTGA mutation) who presented with secondary 
non-cutaneous lesions. The first patient was diagnosed with a squamous cell carcinoma 
(SCC) of the tongue, the second patient with a primary adenocarcinoma of the lung, and 
the third with a SCC originating from the cricoid. Secondary analysis was required to 
show that the latter two presentations were in fact recurrent thyroid cancer. 
Conclusion
These findings suggest that drugs such as sorafenib may induce metaplasia/clonal 
divergence of metastatic thyroid cancer and thus cause diagnostic misclassification. 
Furthermore, sorafenib is potentially involved in the tumorigenesis of secondary non-
cutaneous SCC. These observations should now be confirmed in larger series of patients 
treated with drugs such as sorafenib.
Keywords
Sorafenib, differentiated thyroid cancer, squamous cell carcinoma, squamous 
differentiation, clonal divergence  
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Sorafenib (BAY-43-9006) is an orally active multikinase tyrosine kinase inhibitor (TKI) that 
activates anti-angiogenic and pro-apoptotic pathways, targeting the B-type Raf kinase 
(BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged 
during transfection (RET). Sorafenib is widely approved for the treatment of patients 
with hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC) in well-
defined phases of disease. From June this year sorafenib will also be registered for the 
treatment of patients with thyroid cancer by the European Medicines Agency (EMA). 
Multiple clinical trials have been conducted in a wide range of cancers (lung, thyroid, 
breast, colorectal) using sorafenib as a single agent or in combination treatment (www.
clinicaltrials.gov).  
 Recently published results of a phase III trial of sorafenib in patients with 
advanced radioactive iodine 131-I (RAI) refractory differentiated thyroid carcinoma 
(DTC) showed that sorafenib has clinically relevant antitumor activity and a generally 
well-tolerated profile of adverse events (AEs). The most commonly reported sorafenib-
related AEs in DTC include hand-foot syndrome, hypertension, weight loss, diarrhea and 
rash.(1,2) Recent reports have also suggested a possible causal link between sorafenib 
therapy and the development of cutaneous squamous cell carcinomas (SCC).(3-8) 
 We now describe three patients who received sorafenib during treatment for 




The presence of somatic DNA mutations including BRAF (V600E and V600K), KRAS 
(codon 12/13), and PIK3CA (exons 9 and 20) were determined by quantitative real-time 
PCR (qPCR) with hydrolysis probes (Custom TaqMan® Assay Design Tool, Applied 
Biosystems, Nieuwerkerk a/d IJssel, NL), and when indicated, by standard Sanger DNA 
sequencing on an ABI 3739 automated sequencer (Applied Biosystems, Foster City, CA, 
USA).(9) Tissues were microdissected to enrich for tumor cells and tumor areas were 
selected based on the analysis of a hematoxylin eosin (HE)-stained tissue slide. Tumor 
DNA was subsequently isolated using the Nucleospin Tissue kit (Marcherey-Nagel, 
Bethlehem, PA, USA) according to manufacturer’s protocol.
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PATIENTS
Patient 1
A 67-year-old female was diagnosed with a well differentiated papillary thyroid 
carcinoma (PTC, BRAF c.1799 T>A; p.V600E mutation positive), stage T2N0M0, in 
1989. She underwent a total thyroidectomy and RAI ablation therapy. Local recurrent 
disease was diagnosed ten years later and treated with a left-sided modified radical 
neck dissection, followed by RAI therapy. The post-therapy scintigraphy showed no 
RAI uptake. Six years later routine follow-up with computed tomography (CT) identified 
metastatic disease with multiple lung lesions, the largest measuring 5 mm (2005). A 
total body scintigraphy after RAI therapy showed no uptake of RAI despite elevated 
thyroglobulin levels (68 ug/l), indicating RAI refractory disease. Due to the progression 
of disease two years later (2007) the patient received sorafenib (2 x 400 mg/day initially, 
reduced to 1 x 200 mg/day after 6 months) in the context of a phase II study.(2,10) 
Follow-up showed stable disease according to the Response Evaluation Criteria in Solid 
Tumours (RECIST) 1.0.(11) Thirty-nine months after starting sorafenib, with ongoing 
stable disease, the patient stopped therapy mainly due to diarrhea.
 After starting sorafenib treatment, the patient developed several skin lesions 
(for a summary see Table 1). Furthermore, within 2 months of beginning sorafenib 
therapy the patient developed left-sided tongue complaints, originally histologically 
diagnosed and treated as mucosal hyperplasia with Candida albicans infection. The 
symptoms persisted however and eventually led, 46 months after the initial complaints, 
to the diagnosis of a T2N2cM0 functional irresectable SCC of the tongue (thyroid 
transcription factor (TTF)-1 and thyroglobulin immunohistochemically negative; BRAF 
p.V600E negative) with ipsi-lateral lymph node metastasis (Figure 1). Despite chemo-
radiation therapy with 7 rounds of cisplatin, the  patient died 5 months after diagnosis 
of the SSC.
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SCC on the back 
Candida infection of the tongue
April 2008
Reactive epithelial skin lesion on the back without obvious atypia
Leukokeratosis of the tongue with atypia and inflammation
June 2008 Lesion with inverted follicular keratosis on the lower left leg
September 2009 Trichilemmoma of the nose
March 2010 Irritated verruca seborrhoica upper right leg
May 2010 Reactive epithelial hyperplasia of the tongue due to a candida infection
August 2011
Invasive squamous cell carcinoma of the tongue
Multiple lymph node metastasis of the SCC in the neck region
December 2011 SCC lymph node metastasis in the left axilla
Summary of lesions seen in patient 1 after starting sorafenib treatment November 2007.
Figure 1 Lymph node metastasis of the SCC of the tongue in patient 1
 
Figure 1 Lymph node metastasis of the SCC of the tongue in patient 1 
 
HE staining of a fine needle aspirate (FNA) of a cervical lymph node using a standard embedding 
procedure of cytology material and histologic processing. Atypical squamous cells with (para-)
keratotic horn were seen, indicative of metastasized SCC.   
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Patient 2
The second (male) patient was diagnosed with a T4N1Mx PTC without squamous 
metaplasia (positive for the rare BRAF mutation c.1799-1801het_delTGA, Figure 2) at 
the age 67.(12-14) He underwent a total thyroidectomy with a right-sided lymph node 
dissection, followed by RAI ablation therapy in 2001. In 2004 the patient had recurrent 
disease, and a bilateral para-tracheal lymph node dissection was performed. A year 
later he presented with local recurrent disease and the presence of multiple pulmonary 
metastases. A whole body scintigraphy after RAI therapy showed no RAI uptake, while 
thyroglobulin levels were 133 ug/l, thus demonstrating RAI refractory disease. In 2007, 
the patient was referred to our hospital for inclusion in a phase II trial and received 
sorafenib 400mg twice daily.(2,10) Despite initial stable disease, the patient became 
progressive under sorafenib after 19 months of therapy. The patient was subsequently 
enrolled in a clinical study (RAD001, www.clinicaltrials.gov CRAD001CNL08T) to 
determine the efficacy of everolimus in patients with progressive irresectable recurrent 
or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid 
carcinoma. The patient ceased everolimus therapy 18 months later due to progressive 
disease. A CT showed a new pulmonary lesion and a number of (non)target lesions 
according to RECIST 1.0.(11) Since all conventional or study-based treatment options 
had been exhausted, the patient was referred back to his own hospital where he 
presented 2 months later with progressive dyspnea due to malignant pleural effusion. 
A CT showed multiple bilateral pulmonary metastases and a large right para-tracheal 
lesion. Surprisingly, right-sided pleural fluid cytology elsewhere revealed a primary 
adenocarcinoma of the lung. Immunohistochemistry of embedded cytological material 
showed TTF-1 and cytokeratin (CK) 7 positivity and absence of staining for thyroglobulin, 
cluster of differentiation (CD) 56 and CK20. Additional paired box (PAX) 8 and CK19 
staining in our institute were however positive, indicative of metastatic PTC (Figure 3). 
Molecular testing confirmed this diagnosis with the presence of the previous identified 
BRAF mutation. The patient died a month later due to disease progression.  
Figure 2 BRAF DNA sequencing
 
Figure 2 BRAF DNA sequencing 
 
Identification of a rare BRAF mutation c.1799-1801het_delTGA.
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Figure 3 Pathological analysis of pleural effusion in patient 2
 
Figure 3 Pathological analysis of pleural effusion in patient 2 
FNA of a right-sided pleural effusion after embedding and histological processing.  




FNA of a right-sided pleural effusion after embedding and histological processing.  
: ; B: TTF1 i munohistochemistry (IHC); C: PAX8 IHC
Patient 3 
A 60-year-old male was diagnosed with a T2N0M0 poorly differentiated PTC (BRAF 
c.1799 T>A; V600E mutation positive) in 2002. The patient was treated by total 
thyroidectomy with a left-sided lymph node dissection, followed by RAI ablation therapy. 
Three years later (2005) he presented with multiple pulmonary lesions, non-RAI avid on 
whole body scintigraphy after RAI therapy, and thyroglobulin levels of 127 ug/l. Due to 
disease progression in 2008 the patient was included in a phase II trial (and received 2 
x 400 mg sorafenib daily).(2,10) In the first 6 months a partial response was achieved, 
which was ongoing until therapy discontinuation 32 months later due to complaints of 
diarrhea and hand-foot syndrome. A CT four months after therapy discontinuation still 
showed an ongoing partial response per RECIST 1.0.(11) However, seven weeks later 
the patient presented with respiratory failure due to airway obstruction. A large tumor 
originating from the cricoid was visible on CT scan. Initial histological examination 
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elsewhere concluded that the lesion was a SCC originating from the cricoid. Revision 
of the tumor showed a lesion with squamous differentiation (Figure 4). Although P63 
staining (indicative of squamous differentiation) was positive in a subset of cells, 
immunohistochemistry also showed TTF-1 and thyroglobulin to be focally positive, 
indicative of a PTC recurrence. Surprisingly, the BRAF mutation present in the primary 
tumor was not recovered from this tumor, possibly suggesting clonal divergence after 
sorafenib treatment. Given the fact that local treatment was not an option the patient 
received a tracheal stoma followed by radiotherapy. He died 8 months later due to 
tumor progression.
Figure 4 PTC recurrence in the laryngeal cricoid of patient 3
 
Figure 4 PTC recurrence in the laryngeal cricoid of patient 3 
 
 
In a biopsy from the laryngeal cricoid solid sheets of tumor cells were seen with focal keratinisation. 
Panel A shows the HE stained tissue. Immunohistochemical analysis of TTF-1 (panel B) and P63 
(Panel C) is shown. A large proportion of the cells stained positive for P63, supporting the squamous 
features. However, there was a fraction a cells that stained moderately positive for TTF-1 (thick 
arrow in panel B), partly overlapping with P63 positivity (thin arrow in panel C). Thyroglobulin also 
stained focally positive (not shown). Due to the TTF-1 and thyroglobulin positivity, we favoured 
the diagnosis of recurrent papillary thyroid cancer with remarkable squamous metaplasia over a 
primary laryngeal squamous carcinoma.
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The cases described here present three interesting observations. Firstly, (although 
lacking proven causality) our demonstration of a primary tongue carcinoma that arose 
after long-term sorafenib treatment suggests that treatment with the multikinase 
inhibitor sorafenib may cause other effects additional to squamous skin lesions.(3-8) 
However, since patient 2 was subsequently treated with everolimus, a combined effect 
of sorafenib and everolimus cannot be ruled out. Secondly, we note that metaplastic 
changes or clonal divergence can result in the misdiagnosis of recurrences of thyroid 
cancer. Indeed, clonal divergence at the molecular level might be an aspect of PTC 
with BRAF c.1799 T>A; p.V600E mutations. Thirdly, we identified a rare BRAF mutation, 
c.1799-1801het_delTGA, which will be missed by the allele-specific assays currently in 
use in daily practice in many laboratories.
It has been proposed that BRAF kinase inhibitors can stimulate proliferation 
in cells lacking mutant BRAF via a paradoxical activation of RAF-MEK-ERK1/2 pathway 
signaling in the presence of upstream activation of RAS, thus possibly explaining 
the development of cutaneous SCC.(3-8) This hypothesis was supported by a study 
that analyzed oncogenic mutations in cutaneous SCCs in melanoma patients treated 
with the BRAF inhibitor vemurafenib. This study found that 13 out of 21 tumors 
harbored a RAS mutation.(15) Furthermore, there are several reports on patients 
treated with a BRAF inhibitor who developed secondary tumors. One case has been 
described of a patient on vemurafenib treatment for a melanoma who developed a 
RAS-mutant leukemia correlating with enhanced extracellular signal-regulated kinases 
(ERK) signaling.(16). Another study reports the development of four colonic adenomas, 
one hyperplastic colonic polyp and six gastric polyps in a patient also treated with 
vemurafenib for a melanoma. However, no evidence of RAS mutations was reported 
in any of the adenomas identified in this patient.(17). In addition, progression of  a 
previously present KRAS mutated colon carcinoma due to stimulated ERK signaling was 
reported in a patient with a melanoma treated with dabrafenib.(18) A similar molecular 
explanation might be relevant to the cases we now present, although the presence of 
RAS mutations was not completely tested in the lesions with squamous metaplasia. 
In summary, we described three patients with advanced RAI refractory DTC and 
a history of sorafenib treatment who presented with a secondary non-cutaneous lesion. 
The first patient was diagnosed with a SCC of the tongue; the remaining two patients 
had recurrent disease with altered morphology and molecular biology suggesting clonal 
divergence, with initial diagnoses as a primary adenocarcinoma and SCC, originating 
from the lung and cricoid respectively. Although the possibility that these tumors were 
already present in the form of micrometastases prior to sorafenib treatment cannot 
be excluded, these observations are quite remarkable. It is therefore important that 
a pathologist is familiar with the patient’s medical history and treatment and that the 
possibility of  unusual presentation is kept in mind when considering secondary lesions. 
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ABSTRACT
Objective
Until recently, advanced medullary thyroid cancer (MTC) had few treatment options 
except surgery. Everolimus is a rapamycin derivative that targets mTOR, and has 
shown encouraging results in neuroendocrine tumors both in vitro and in vivo. As part 
of a prospective phase II clinical trial, we analyzed the safety of everolimus and efficacy 
on tumor progression in advanced MTC.  
 
Methods
Seven patients with per RECIST 1.1 documented progressive metastatic MTC, were 
included and received everolimus 10mg daily. The primary objective was to determine 
treatment efficacy. Secondary endpoints included progression-free survival (PFS), 
overall survival (OS), toxicity and pharmacokinetics (PK).
 
Results
The median duration of follow-up was 28 weeks (17-147). Five patients (71%) showed 
SD, of which 4 (57%) for >24 weeks. Median PFS was 33 weeks (95%CI:8-56), and 
median OS was 30 weeks (95%CI:15-45). Toxicity was predominantly grade 1 or 2 and 
included mucositis (43%), fatigue (43%) and hypertriglyceridemia (43%). Four MTCs 
(57%) harbored the somatic RET mutation c.2753T>C,p.Met918Thr. The best clinical 
response was seen in a MEN2A patient. The PK characteristics were consistent with data 




This study suggests that everolimus exerts clinically relevant antitumor activity in 
patients with advanced MTC. Given the high level of clinical benefit and the relatively 
low toxicity profile, further investigation of everolimus in these patients is warranted.  
Keywords 
Medullary thyroid cancer, everolimus, phase II, clinical trial, targeted therapy
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Medullary thyroid cancer (MTC) is a neuroendocrine tumor derived from the calcitonin-
producing thyroid C cells and accounts for 3-5% of cases of thyroid cancer [1]. Until 
recently, besides surgery few curative and palliative treatment options were available 
for patients with MTC. Conventional treatment modalities have disappointing outcomes 
in most patients with MTC, indicating the need for new treatments.
The American Thyroid Association therefore recommends that these patients should 
be enrolled in clinical trials. Concurrently, an increased understanding of thyroid 
tumorigenesis has led to the identification of potential targets, with novel therapeutic 
agents now able to target these biological abnormalities.
 In addition, many genetic alterations affecting tyrosine kinase signaling 
pathways have recently been identified in various forms of thyroid cancer such as the 
activating RET mutations present in > 95% of hereditary MTC and in 20-50% of sporadic 
MTC [2,3]. The phosphatidylinositol-3-kinase (PI3K)/Akt pathway regulates cell growth, 
proliferation and survival in all thyroid tumor subtypes [4]. An important effector in 
the PI3K/Akt pathway is the mammalian target of rapamycin (mTOR). Activation of 
the mTOR serine/threonine protein kinase has been reported in a variety of malignant 
tumors, including thyroid tumors, with an estimated 70% of all tumors showing mTOR 
up-regulation [5]. 
As a result of this accrued understanding of the biological basis of thyroid 
cancer development, several clinical trials with multi-target tyrosine kinase inhibitors 
(TKIs) have been conducted. Everolimus is an orally available derivative of rapamycin, 
targeting mTOR. Everolimus exerts its activity through high affinity interaction with an 
intracellular receptor protein, the immunophilin FKBP12. The FKBP12/everolimus complex 
subsequently interacts with the mTOR protein kinase, inhibiting downstream signaling 
events involved in regulation of the G1 to S-phase transition[6]. The use of everolimus in 
neuroendocrine tumors has shown encouraging results, both in vitro and in vivo [7-9]. 
 We initiated a phase II study to assess safety and efficacy of everolimus on 
tumor progression in patients with advanced thyroid carcinoma (THYRRAD, www.
clinicaltrials.gov CRAD001CNL08T). In addition, pharmacokinetic parameters were 
assessed. Here we present a subgroup analysis of seven MTC patients.  
524722-L-bw-Schneider
Processed on: 9-10-2018 PDF page: 62
62
Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary 
thyroid carcinoma; subgroup results of a phase II trial
MATERIALS AND METHODS
Patients
Eligibility criteria were the presence of per RECIST 1.1 (Response Evaluation Criteria 
In Solid Tumors) documented progressive metastatic or inoperable MTC in the 12 
months prior to therapy [10]. Patients were required to be ≥ 18 years of age with a 
Karnofsky performance score > 70%. Laboratory requirements consisted of adequate 
bone marrow function (absolute neutrophil count ≥ 1,500/µL, platelets ≥100,000/µL, 
hemoglobin ≥ 5.6mm/L), liver function (serum bilirubin ≤ 1.5× upper limit of normal 
(ULN), serum ALT and AST ≤ 2.5× ULN) and renal function (serum creatinine ≤ 2× 
ULN). Women of childbearing age were required to have a negative serum or urinary 
pregnancy test within 14 days prior to the first dose of the study drug. Patients were not 
excluded based on number or type of prior therapies received, with the exception of 
prior targeted therapy with everolimus or other mTOR inhibitors. 
Written informed consent was provided by all patients before enrollment in 
the trial. The study protocol was approved by the Institutional Review Board of Leiden 
University Medical Center and performed in the university hospitals of Leiden and 
Groningen. This study was registered at ClinicalTrials.gov (#NCT01118065).
Study design
We performed a non-randomized, open-label, multi-center, single arm phase II trial of 
everolimus in patients with advanced thyroid cancer; 28 patients with differentiated 
(DTC), 7 patients with anaplastic (ATC) and 7 patients with medullary (MTC) thyroid 
carcinoma were included. The primary objective was to determine the efficacy 
(response rate and stable disease >24 weeks) of everolimus. Secondary objectives 
were determination of the maximum percentage of tumor reduction for target lesions, 
describing activity time to event endpoints and assessment of toxicity, adverse events 
(AEs) and pharmacokinetics. Eligibility assessments, including a review of medical 
history and prior treatments, physical examination, and disease staging assessments 
were performed within 4 weeks prior to the first dose of everolimus. Baseline evaluations, 
comprising performance status, vital signs and laboratory tests were assessed within 
2 weeks prior to initiation of therapy. Everolimus was administered at a dose of 10 mg 
orally once daily until disease progression, unacceptable toxicity, death, or patients’ 
own request. Objective tumor response and time of progressions was measured 
according to the RECIST criteria version 1.1 every 12 weeks (± 2 weeks) during the first 
year, thereafter every 6 months and at study discontinuation.
 Safety assessments were made every 4 weeks by adverse event collection, 
standard clinical and laboratory tests, and physical examinations. In case of toxicity or 
AEs requiring dose adjustments, drug dosing was interrupted or modified according 
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to the guidelines. AE monitoring was continued for at least 4 weeks following the last 
dose of study treatment. The incidence, grade and casual relationship of adverse events 
were graded with the use of Common Terminology Criteria for Adverse Events (CTCAE, 
version 4.0). Following study discontinuation, all patients were followed for survival for 
4 weeks.
Laboratory parameters 
Serum thyroid stimulating hormone (TSH), free thyroxine (T4), carcinoembryonic 
antigen level (CEA), calcitonin and safety parameters were assessed at all visits. Safety 
parameters included a total blood count as well as serum levels of sodium, potassium 
and creatinine, lipids, coagulation and renal and liver function.
Somatic mutation spectrum screening 
DNA for mutation analysis was available for six MTC tumors. Somatic hotspot mutations 
were identified using a custom Ampliseq panel that targets somatic hotspot mutations 
in 22 genes using Ion Torrent Ampliseq sequencing chemistry (Life Technologies, Foster 
City, CA. Details available on request). The samples were sequenced using the Ion 
Torrent PGM (Life Technologies, Foster City, CA). FastQ sequence data files from the Ion 
Torrent PGM were analyzed with NextGENETM software (version v.2.3.4.2, Softgenetics, 
State College, PA) using standard settings for somatic mutation analysis, excluding 
known polymorphisms. 
Pharmacokinetics
In order to measure blood concentration levels of everolimus and assess everolimus 
steady-state pharmacokinetics (PK), patients were admitted to hospital for PK sampling 
on day 15 of each treatment cycle. Samples were collected in EDTA tubes at pre-dose 
and at 1, 2, and 3 hours after everolimus intake. Additional PK sampling at 4, 5, 6, 7 and 
8 hours after everolimus intake was optional. Everolimus concentrations in whole blood 
were determined using a validated Ultra Performance Liquid Chromatography - Tandem 
Mass Spectrometric (UPLC-MS/MS) assay. Pharmacokinetic parameters were calculated 
with a non-compartmental approach using WinNonLin and included the Area Under 
the Concentration-time curve over the dosing interval (AUC0-24hr), trough everolimus 
concentration (Ctrough), time to reach peak concentration (Tmax), peak concentration (Cmax) 
and the elimination half-life (T½). 
Statistical analysis 
Seven MTC patients were analyzed as a separate cohort for response rate. If no responses 
were present in this patient group, we could conclude that further investigation of 
everolimus in MTC patients is unwarranted. Endpoints were reported as median (range) 
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or proportions. Estimates of progression-free survival  (PFS) (time from starting study 
drug to progression or death, whichever occurred first) and OS (time from starting study 
drug to the date of death by any cause), with associated 95% CIs, were obtained using 
the Kaplan-Meier method. Patients who were progression-free and/or alive at the time 
of data analysis were censored. Variables influencing the response to everolimus were 
analyzed with binominal logistic regression. The calculations were performed using 




All 7 patients with medullary thyroid carcinoma were included in this efficacy and 
tolerability analysis. The follow-up of the study ended on 31 December 2013 with a 
median follow-up of 28 weeks (range 17-145 weeks). The median everolimus treatment 
period was 17 weeks (range 6-116 weeks). One patient was still on everolimus treatment 
at the time follow-up ended. 
Baseline characteristics are listed in table 1. Two (29%) females and 5 (71%) 
males were included, with a median age of 53 years (range 44-74). At study entry, 1 (14%) 
patient had locally advanced disease, while the other 6 (86%) had distant metastasis. 
None of the patients were treatment-naïve.
Efficacy
Efficacy analysis showed promising results. Five patients (71.4%) showed stable 
disease (SD), with 4 (57.1%) having SD lasting >24 weeks. Median SD duration was 24 
weeks (range 17-117 weeks). At the time of data analysis (31-12-2013), 1 patient still had 
ongoing SD. There were no complete (CR) or partial (PR) responses. Data on efficacy 
are given in table 2 and figure 1.
 Estimated median PFS was 33 weeks (95% CI: 8-56 weeks). The median overall 
survival (OS) was 30 weeks (95% CI: 15-45 weeks). Disease progression and survival 
appeared not to be influenced by age, gender, disease site, mutational status, everolimus 
blood concentration or dose reduction. Changes in calcitonin and CEA could not be 
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Table 1 Baseline characteristics 
All patients (n=7)
Gender (n, %) 





Age (year; median, range) 53 (44-74)
Time from diagnosis (year; median, range) 4.3 (1.6-25.6)
Initial TNM stage (n, %) 
  IB (T2N0M0) 
  IIB (T2-3 N0-1 M0) 
  IIIA (T1-3 N1-2 M0) 








Tumor extent at study entry (n, %) 





No. of disease sites (n, %) 
  1 
  2 





Mutational status (n, %) 
  RET M918T 
  MEN-IIA 





1 (14)  
1 (14)
Prior treatment (n, %) 
  Surgery 
  Radiation therapy 





ˣ  3 patients received XL184; 1 patient showed an ongoing PR for 14 months before he 
became progressive, 2 had PD as best result after 12 and 24 weeks. ˚ 1 patient had vandetanib for 
8 months, followed by 3 months of sunitinib, which was stopped due to side effects. 
Table 2 Efficacy analysis
Parameter 
Median duration of treatment (weeks; range) 17 (6-116)
Cumulative dose of everolimus (mg; median, range) 1200 (440-8012)
Median duration of follow-up (weeks; range) 28 (17-147)
Best response by RECIST 1.0 (n, %)
   Complete response
   Partial response
   Stable disease





Overall disease control 5 (71)
Median duration of SD (weeks; range) 24 (17-116)‡
Median PFS (weeks; 95% CI) 33 (8-56)
Median OS (weeks; 95% CI) 30 (15-45)
RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, PFS progression-free 
survival, OS overall survival.
† 4 of 5 patients showed SD >24 weeks, ‡ at time of data analysis, 1 patient still had ongoing SD.
524722-L-bw-Schneider
Processed on: 9-10-2018 PDF page: 66
66
Beneficial effects of the mTOR inhibitor everolimus in patients with advanced medullary 
thyroid carcinoma; subgroup results of a phase II trial
Figure 1 Kaplan-Meier curves of (A) overall survival and (B) median progression-free survival
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Table 3 Changes in calcitonin and CEA during treatment 






























































































CT calcitonin, CEA carcinoembryonic antigen level, - there was no reduction in CT or CEA compared 
to baseline, ‡ there was no increase in CT compared to baseline +patient is still on everolimus 
treatment
Figure 2 Serum calcitonin and CEA concentrations per patient over time 
 
A: serum calcitonin over time for all patients, B: close-up of figure A for patients 2, 5 and 6, C: 
serum CEA for all patients, D: close-up of figure C for patients 1, 4, 5, 6 and 7.
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Toxicity
Three patients (43%) required dose reduction due to toxicity. One patient (14%) 
discontinued the study after 12 weeks due to complaints of fatigue and peripheral 
edema. All observed AEs are listed in table 4. Treatment-related AEs were 
predominantly grade 1 or 2, with the most common events including mucositis, fatigue 
and hypertriglyceridemia. Grade 3 AEs consisted of fatigue (29%), peripheral edema 
(14%), hypercholesterolemia (14%), hyperglycemia (14%), pneumonia (14%) and 
pneumonitis (14%). No grade 4 AEs were observed. One (14%) serious adverse event 
(SAE) was reported when a patient was hospitalized due to acute stomach pain after 
5 weeks of everolimus treatment. A gastroduodenoscopy revealed no abnormalities 
and the complaints resolved spontaneously. The majority of AEs were controllable with 
dose reduction, medication or supporting measures. There appeared to be no relation 
between toxicity and performance state or age. 
One patient with relatively high everolimus blood plasma concentrations 
(AUC0-24hr, 960µg*hr/L), as shown in figure 3, also showed more profound toxicity. This 
patient suffered a total of 13 AEs, whereas the median number of AEs was 5 (range 
3-13). Co-medication and a high hematocrit were excluded as possible causes of the 
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Table 4 Adverse events
 
                                                               All
Grades Number of patients 
(% of category)
Event
  Number of patients
   (% of total (n=7))    
1 2 3 4
Mucositis 3 (43) 2 (67) 1 (33)
Fatigue 3 (43) 1 (33) 2 (67)
Hypertriglyceridemia 3 (43) 1 (33) 2 (67)
Peripheral edema 2 (29) 1 (50) 1 (50)
Anorexia  2 (29) 2 (100)
Diarrhea 2 (29) 1 (50) 1 (50)
Rash 2 (29) 1 (50) 1 (50)
Pneumonia 2 (29) 1 (50) 1 (50)
Liver function # 2 (29) 1 (50) 1 (50)
Hypercholesterolemia 2 (29) 1 (50) 1 (50)
Hypophosphatemia 2 (29) 2 (100)
Hypoparathyroidism 2 (29) 2 (100)
Weight loss 1 (14) 1 (100)
Nausea 1 (14) 1 (100)
Vomiting 1 (14) 1 (100)
Constipation 1 (14) 1 (100)
Allergic reaction 1 (14) 1 (100)
Dry skin 1 (14) 1 (100)
Itch 1 (14) 1 (100)
Asthenia 1 (14) 1 (100)
Anemia 1 (14) 1 (100)
Hyperglycemia 1 (14) 1 (100)
Cough 1 (14) 1 (100)
Dyspnea 1 (14) 1 (100)
Pneumonitis 1 (14) 1 (100)
All AEs graded according to Common Terminology Criteria for Adverse Events version 4.0
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Figure 3
Individual observed concentration versus time profiles for everolimus
Mutation analysis
One of the 7 MTC patients was excluded from the mutation analysis because no 
tumor tissue was available. Of the 6 remaining patients, one MEN2A patient carried a 
germline RET c.1858T>C, p.Cys620Arg mutation. Using targeted nextgen sequencing 
of tumors, four showed a somatic RET c.2753T>C, p.Met918Thr mutation, including 
one that also carried an EGFR c.2543C>T, p.Pro848Leu mutation (see supplementary 
table 1). It is noteworthy that the MEN2A patient showed the best response to 
everolimus treatment, with the longest period of stable disease.
Pharmacokinetics
One patient completed only the short PK sampling schedule; all other patients 
participated in the extended sampling schedule up to 8 hours after everolimus intake. 
Individual everolimus concentrations versus time profiles are shown in figure 3. 
A summary of everolimus pharmacokinetics is shown in table 5. The median (range) 
AUC0-24hr for everolimus was 421 µg*hr/L (257-960 µg*hr/L) and the median Ctrough was 
7.4µg/L (4.0-18.3 µg/L). The median Tmax was 1.0 hour and the median Cmax was 48.2 
µg/L. The median T1/2 of everolimus was 13.8 hours (10.9-32.4 hr).
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Table 5 Summary of everolimus pharmacokinetic parameters
Median (range) Mean SD CV%
AUC0-24hr (µg*hr/L) 421 (257-959) 442 246 55.7%
Ctrough (µg/L) 7.4 (4-13.8) 9.0 5.2 57.8%
Tmax (hr) 1 (0.33-3.08) 1.2 0.9 75.0%
Cmax  (µg/L) 48.2 (37.8-102.3) 59.4 23.8 40.1%
T1/2 (hours) 13.8 (10.9-32.4) 16.5 7.5 45.5%
AUC area under the concentration time curve, Cmax peak plasma concentration, CV% coefficient of 
variation, SD standard deviation, Tmax time to reach peak plasma concentration.
DISCUSSION
Until recently, surgery was accompanied by only limited curative and palliative 
treatment options for patients with MTC, emphasizing the need for new therapies. Using 
everolimus, a significant dose-dependent inhibition in cell proliferation was observed 
in two medullary thyroid cancer cell lines [11]. Everolimus significantly inhibited cell 
viability in a dose and time-dependent fashion, and diminished phosphorylation of 
mTOR in a TT thyroid cancer cell line and cultured human MTCs [12]. Two case reports 
comprising three  patients with advanced MTC showed beneficial effects of everolimus 
[11,13]. Recently, a phase II study in patients treated with everolimus, with advanced 
thyroid cancer of all histologic subtypes (n=38), reported a partial response (PR) and 
stable disease (SD) in 5% and 76% of patients, respectively. Median progression-free 
survival (PFS) was 47 weeks [14]. 
Our phase II trial on advanced MTC showed promising results, with stable 
disease in 5 of 7 (71%) patients. The median PFS and OS of 33 and 30 weeks respectively, 
were also promising. The lack of PRs is easily explained by the fact that these tumors 
are slowly progressive and PRs were therefore not expected. Due to the fact that only 
seven patients were included, we were not able to identify parameters significantly 
influencing response or survival. Although several trials have reported a biochemical 
CEA and calcitonin response that reflects the radiological response, these changes were 
not always significant and in our study and we were unable to confirm this correlation 
[11, 14-16]. 
 Although EGFR overexpression is frequently seen in medullary thyroid cancer, 
EGFR mutations are rarely described [17]. The EGFR P848L mutation we identified is 
situated close to the L858R mutation, a well-known target in non-small cell lung cancer. 
However, the P848L mutation has been described in patients with non-small cell lung 
carcinoma and is thought to be a functionally silent polymorphism, insensitive to 
gefitinib treatment [18,19].
The MEN2A MTC patient showed the best response upon everolimus therapy. 
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Apart from the treatment effect, the RET c.1858T>C, p.Cys620Arg mutation has been 
associated with a less aggressive phenotype compared to other MEN2A-related 
mutations such as the c.2753T>C p.Met918Thr mutation or one of the classic mutations 
in exon 11 at codon 634 [20]. To the best of our knowledge, this is the first report of 
administration of everolimus to a MEN2A patient. 
Everolimus was generally well tolerated, with the majority of AEs manageable 
and similar to previously reported toxicities [14,21]. The PK characteristics were also 
consistent with phase I pharmacokinetic studies  investigating everolimus (10 mg once 
daily) in solid and hematological malignancies [22-24]. The inter-patient variability in 
PK was also comparable to previous research. Although based on the short sampling 
schedule, the patient with the highest exposure also showed the most extensive toxicity 
profile, perhaps related to higher everolimus plasma concentrations. 
Although everolimus treatment has shown encouraging results in patients 
with a variety of solid tumors, it has to be noted that its inability to inhibit mTORC2 
may imply an inability to achieve a potent and long term antitumor effect. Hisamatsu 
et al. showed that simultaneous inhibition of mTORC2 during everolimus treatment 
enhanced the anti-tumor effect of everolimus and prevented clear cell carcinoma cells 
of the ovary from acquiring resistance to RAD001 [25]. Furthermore, several reports has 
been published describing a feedback loop between the mTOR pathway and RAS/MAPK/
ERK signaling, leading to activation of a different prosurvival signaling pathway upon 
mTOR inhibition. This mechanism of action suggests that treatment with everolimus 
as a single molecular target agent may not be sufficient, emphasizing the interest of 
studies with everolimus combined with other targeted agents [6,14,26].
In conclusion, given the high rate of clinical benefit and the relatively low toxicity 
profile found in this MTC subgroup analysis, we believe that further investigation in 
larger cohorts of MTC patients is now warranted, using everolimus either as a single 
agent or in sequential or combination therapy.
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ABSTRACT 
Background 
Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. 
Many patients treated with the registered fixed 10 mg dose once daily are in need of dose 
interruptions, reductions or treatment discontinuation due to severe adverse events. 
This study determined the correlation between systemic everolimus exposure and 
toxicity. Additionally, the effect of different covariates on everolimus pharmacokinetics 
(PK) was explored. 
Methods 
Forty-two patients with advanced thyroid carcinoma were treated with 10 mg 
everolimus once daily. Serial pharmacokinetic sampling was performed on day 1 and 
15. Subsequently, a population PK model was developed using NONMEM to estimate 
individual PK values used for analysis of an exposure-toxicity relationship. Furthermore, 
this model was used to investigate the influence of patient characteristics and genetic 
polymorphisms in genes coding for enzymes relevant in everolimus PK.
Results
Patients who required a dose reduction (n = 18) due to toxicity at any time during 
treatment had significant higher everolimus exposures (mean AUC0-24 (SD) 600 (274) 
vs. 395 (129) µg*hr/L, P = 0.008) than patients without a dose reduction (n = 22). A 
significant association between everolimus exposure and stomatitis was found in the 
four-level order logistic regression analysis (P = 0.047). The presence of at least one 
TTT haplotype in the ABCB1 gene was associated with a 21% decrease in everolimus 
exposure.
Conclusion
The current study showed that dose reductions and everolimus induced stomatitis were 
strongly associated with systemic everolimus drug exposure in patients with cancer. 
Our findings confirm observations from another study in patients with cancer and show 
us that everolimus is a good candidate for individualized dosing in patients with cancer.
Keywords
Everolimus, Exposure-toxicity, Individualized dosing, Pharmacogenetics, Population 
pharmacokinetics
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Everolimus is an orally administered rapamycin derivative inhibiting the mammalian 
target of rapamycin (mTOR) [1]. This is a key signaling molecule in the phosphatidylinositol 
3-kinase (PI3K)/Akt pathway which is involved in the regulation of growth, proliferation, 
metabolism, survival and angiogenesis of cells and often dysregulated in cancer [1]. 
Currently, everolimus is registered for the treatment of advanced hormone receptor 
positive (HR+), human epidermal growth factor-2 negative (HER2-) breast cancer in 
postmenopausal women in combination with exemestane, for metastatic renal cell 
carcinoma (mRCC), for irresectable or metastatic pancreatic neuroendocrine tumors 
(pNET) and subependymal giant cell astrocytoma (SEGA) [2-4].
Despite its proven efficacy, everolimus is also associated with a number of serious 
side effects. Most common toxicities associated with everolimus therapy include 
stomatitis, rash, fatigue, diarrhea, infections, nausea, loss of appetite, hematologic 
toxicities, dyspnea, noninfectious pneumonitis and metabolic abnormalities such as 
hypercholesterolemia and -glycaemia [5]. While it is reported that the majority of these 
adverse events are manageable and of mild to moderate severity, many patients are in 
need of dose interruptions, reductions or treatment discontinuation due to toxicity [6]. 
Indeed, in the pivotal breast cancer, mRCC and pNET phase III trials, 10 to 35% of the 
patients discontinued everolimus treatment due to adverse events [2-4]. In addition, 
~62% of the patients needed dose interruptions or reductions compared to 12-29% in 
the placebo arms [2,4].
The large number of dose reductions and treatment discontinuation make toxicity 
currently one of the main challenges in the optimal use of everolimus for the treatment 
of cancer. In oncology, everolimus is registered as a fixed oral dose of 10 mg once 
daily. However, in transplantation medicine therapeutic drug monitoring (TDM) with 
individualized dosing is routinely applied due to everolimus’ narrow therapeutic 
window and high inter-patient variability in pharmacokinetics (PK) [7]. In transplantation 
medicine, everolimus is used as an immunosuppressant to prevent rejections. Dose 
individualization is not only applied to prevent toxicity, but also to optimize treatment 
efficacy. In oncology, the same high inter-patient variability in PK is seen (AUC; 45 CV%, 
Ctrough; 60 CV%) [8]. This substantial variability, in combination with the fixed 10 mg 
dosing, results in large differences in everolimus exposure between patients. This could 
result in either supra-therapeutic drug exposure with an increased incidence of toxicity, 
but also in sub-therapeutic drug exposure leading to decreased anticancer effects.   
The primary objective of this study was to assess the correlation between everolimus 
exposure and toxicity in patients with advanced thyroid cancer. Additionally, we 
explored the influence of different covariates on everolimus PK, including genetic 
polymorphisms in genes encoding enzymes involved in the absorption and metabolism 
of everolimus.    
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MATERIAL AND METHODS
Patients
Forty-two patients were enrolled in this phase II study investigating the efficacy 
and pharmacokinetics of everolimus for the treatment of progressive or recurrent, 
unresectable or metastatic thyroid cancer. The efficacy data of this study will be reported 
separately. Participating medical centers were the Leiden University Medical Center 
and the University Medical Center Groningen. Patients were treated continuously with 
everolimus at an once daily oral dose of 10 mg until tumor progression, unacceptable 
toxicity, death or discontinuation from the study for other reasons. Toxicities were 
assessed at baseline, day 1, 14 and 28 of therapy and monthly thereafter according to 
the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events 
(CTC-AE) version 4.0. Dose adjustments were permitted for adverse events suspected 
to be related to everolimus. The first dose reduction was to 5 mg once daily. If another 
dose reduction was needed, everolimus was dosed as 5 mg every other day. The study 
was approved by the institutional ethics committees (Leiden University Medical Center 
and University Medical Center Groningen, The Netherlands) and all patients gave 
written informed consent before entering the study.
Pharmacokinetic sample collection and analysis
For everolimus PK assessment, whole blood samples were obtained at day 1 and 15 
of therapy. Samples were collected into EDTA-tubes at pre-dose and 1, 2, and 3 hours 
after everolimus intake (sparse schedule). More extensive PK sampling at 4, 5, 6, 7 and 
8 hours after everolimus intake was optional for patients (extensive schedule). Samples 
were stored at -20 °C until the day of analysis.
Everolimus concentrations in whole blood were measured using a validated Ultra 
Performance Liquid Chromatography - Tandem Mass Spectrometric (UPLC-MS/MS) 
assay. Validation of the assay was performed according to the EMA guidelines of 
bioanalytical method development [9].  The calibration line was linear over the range 
from 2 to 160 µg/L and the lower limit of quantification (LLOQ) was 0.6 µg/L. Assay 
performance was in agreement with guidelines for bioanalytical method development 
and validation.
Pharmacogenetic analysis
Single Nucleotide Polymorphisms and haplotype selection
Everolimus is metabolized by the cytochrome P450 (CYP) enzymes CYP3A4, CYP3A5 
and CYP2C8 and is also a substrate for the efflux pump P-glycoprotein (P-gp) encoded 
by the ABCB1 gene [10]. The nuclear pregnane X receptor (PXR; NR1I2) regulates the 
expression of CYP3A4 and could therefore also influence everolimus PK [11]. Eleven 
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single nucleotide polymorphisms (SNPs) in these genes were selected based upon 
a candidate gene approach (Supplementary Data S1, online). For the ABCB1 and 
CYP2C8 gene, selected SNPs were used for haplotype analysis performed in gPLINK 
(Supplementary Data S2, online). Haplotypes were set at a certainty greater than 0.97. 
For the ABCB1 and CYP2C8 gene, only haplotypes and no individual SNPs were tested. 
Genotyping assays
Germline DNA was isolated from 400 µl EDTA-blood using MagNa Pure Compact 
(Roche, Almere, the Netherlands). DNA concentrations were thereafter measured 
using Nanodrop (Isogen, De Meern, The Netherlands). Genotyping was performed 
using pre-designed genotyping assays (Supplementary Data S1, online). Samples 
were analyzed on a Viia7 real-time PCR system according to the manufacturers’ 
instruction (Life Technologies, Bleiswijk, The Netherlands). Call rates of all assays were 
>98%. As a quality control, at least 5% of the samples were genotyped in duplicate. 
No inconsistencies were observed. Minor allele frequencies (MAF) of all 11 SNPs were 
calculated and compared with reported MAF for European Populations (HAPMAP). No 
significant deviations were observed and derived allele frequencies were all in Hardy-
Weinberg equilibrium (P ≥ 0.05) (Supplementary Data S1, online).
Pharmacokinetic modelling
Base model
Thirty patients completed the extensive PK sampling and ten patients the sparse PK 
sampling schedule. After PK sampling, nonlinear mixed-effects modeling (NONMEM) 
was used to describe the population pharmacokinetics of everolimus. Subsequently, the 
developed population PK model was used to estimate individual everolimus exposure 
both in terms of AUC0-24 by using clearance as well as with use of by the model predicted 
Ctrough levels. NONMEM version 7.2 (Icon Development Solutions, Ellicott City, MD, USA) 
was used with Piranã (version 2.9.0) as the modelling environment. Statistical software 
package R (version 2.15.1) was used for handling of data and plots generation. We also 
used NONMEM to explore the influence of different covariates on everolimus PK.
A first-order conditional estimation method with interaction (FOCE-I) was used to fit 
models throughout the building process. One- and two-compartment models with first-
order elimination were explored. It was also assessed whether there was a change in 
clearance from day 1 to day 15 of treatment. Model selection was based on goodness of 
fit and statistical significance. An adjusted model was chosen over the original model if 
the drop in the objective function value (OFVs) was > 3.84 (P < 0.05 with one degree of 
freedom (df), assuming χ2-distribution).
Since the bioavailability (F) of everolimus is unknown, F was fixed at 1 and PK parameter 
estimates reported are proportional to F except Ka. In addition, both clearance (Cl/F) and 
the volume of distribution (Vd/F) were allometrically scaled [12]. 
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Covariate analysis
After the base model was determined, covariates were tested to explore the influence 
of bilirubin, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), 
creatinine, body surface area (BSA) and haematocrit on Cl/F. Individual effect sizes 
were estimated with the formula Cl/Ftypical value = θ1 * (COV/COVmedian)
θ2
, whereby θ1 is the 
population estimate for Cl/F, COV the tested covariate and θ2 the covariant effect size 
estimate. 
The influence of SNPs and haplotypes were all tested as a covariate on Cl/F, except 
for ABCB1 haplotypes which were tested for an effect on F as this is physiologically 
more plausible. Effect sizes were estimated with the formula Cl/Ftypical value (or F) = θ1 
* θ2
^pg1 * θ3
^pg2, whereby θ1 is the population Cl/F or F estimate in wild-type patients, 
θ2 the covariate effect size of the heterozygote mutation status and θ3 the effect size 
of the homozygote mutation status. The heterozygote (pg1) and homozygote (pg2) 
mutation status was scored as 1 if present or 0 if not present. If the genotype frequency 
was < 0.1, homozygote mutant and heterozygote mutant genotypes were combined 
(Supplementary Data S1 and S2, online)
All covariates were first tested for statistical significance with univariate forward 
inclusion into the base model (drop in OFV > 3.84, df = 1, P < 0.05). After inclusion 
of significant covariates in the intermediate model, a stepwise backward elimination 
procedure was performed. Covariates were remained in the final model if the threshold 
for statistical significance of backward elimination was reached (increase in OFV > 6.64, 
df = 1, P < 0.01).     
Evaluation of model fit
Next to goodness of fit plots, a visual predictive check (VPC) was used to assess 
the performance of the final model by comparing the 10th and 90th percentiles of the 
simulated concentrations with those of the observed concentrations. In addition, a 
bootstrap analysis was performed to evaluate the precision of parameter estimation. 
Shrinkage in inter-individual variability and residual errors were automatically calculated 
by NONMEM.
Assessment of systemic exposure toxicity relationship
Selection of toxicities
In this study, all experienced toxicities were scored according to CTC-AE version 4.0. 
However, due to the number of patients included, only a limited number of toxicities 
were selected to be tested for an association with everolimus exposure in order to 
prevent false positive findings. 
We choose dose reductions as the first outcome of toxicity as this is the sum of all different 
toxicities experienced by patients and these are also the toxicities that lead to clinical 
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action by the treating physician. In addition, we selected stomatitis and pneumonitis 
as toxicity outcomes. The rationale for selection of these toxicities was based on their 
prevalence and the fact that these toxicities are 1) objectively measurable, 2) clinically 
relevant and 3) untreatable and therefore leading to dose reductions or discontinuation 
of therapy. Toxicities were scored as the highest grade experienced until dose reduction 
and if no reduction occurred until the end of study.
Statistical analysis
The difference in day 15 steady-state everolimus exposure (AUC0-24 and Ctrough) between 
patients with and without dose reductions was tested with an unpaired t-test. The 
relationships between day 15 everolimus exposure (AUC0-24 and Ctrough) and stomatitis 
and pneumonitis were evaluated using a four-level ordered logistic regression in SPSS 
version 20.0 (IBM). 
RESULTS
Patient characteristics
Forty-two adult patients with thyroid carcinoma, 22 men and 20 women were included 
in the phase II trial that investigated everolimus for the treatment of thyroid cancer. Of 
these patients, 28 (66.7%) had differentiated, 7 (16.7%) had undifferentiated (anaplastic) 
and 7 (16.7%) had medullary advanced thyroid carcinoma. Two patients were excluded 
for PK analysis; in one patient no PK samples were collected, and in the other patient 
no measurable everolimus levels could be detected. Patient baseline characteristics are 
shown in Table 1. 
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Table 1. Patient baseline characteristics
Characteristic
N 40






Length (cm) 173 (154 - 189)
Weight (kg) 75 (45 - 105)
Hematology
  WBC (× 109/L)
  ANC (× 109/L)
  Platelets (× 109/L)
  Hemoglobin (mmol/L)
  Haematocrit
7.1 (3.6 - 25)
4.8 (2.7 - 13.0)
254 (147 - 995)
7.5 (5.3 - 10.7)
0.39 (0.29 - 0.50)
Chemistry
  AST (U/L)
  ALT (U/L)
  Creatinine (µmol/L) 
  Total bilirubin (µmol/L)
22 (12 - 61)
22 (7 - 19)
66 (42 - 205)
9 (4 - 16) 
Tumor type (n)
  Differentiated 
  Undifferentiated 




Data are presented as median (range) unless stated otherwise. Abbreviations: ALT, alanine 
aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; WBC, white 
blood count.
Pharmacokinetics 
A total of 669 samples from 40 patients were used to build the population PK model. 
The pharmacokinetic data for everolimus were best described by a two-compartmental 
model with first order absorption and first order elimination from the central 
compartment (Supplementary Data S3, online). No difference in clearance over time 
between day 1 and day 15 of treatment was found.
Forward inclusion of BSA, creatinine, ASAT, ALAT, bilirubin and haematocrit did not 
improve the PK model and no association between these covariates and clearance was 
found. With forward inclusion of the ABCB1 TTT and CCG haplotype the base model 
significantly improved (ΔOFV = -7.2 and -6.4 respectively, P <0.05). The other SNPs 
and the CYP2C8 haplotype did not improve the model. With multivariate backward 
elimination, only the presence of at least one ABCB1 TTT haplotype remained significant 
(ΔOFV = 9.6, P <0.01). A 21% decrease in F was observed in the presence of at least one 
ABCB1 TTT haplotype. Inclusion of this covariate in the final PK model, reduced the 
inter-patient variability in Cl/F from 38.1 to 35.1 CV%. Parameter estimates of the base 
and final model are shown in Table 2. 
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Evaluation of the final model was, next to inspection of the goodness of fit plots, done 
with VPC and a bootstrap procedure. Results of the VPC show that predicted and 
observed concentration intervals are almost identical, indicating accuracy and good 
predictive performance of the final model (Figure 1). There is a small tendency for a 
difference between predicted and observed concentrations in the absorption part of 
the curve due to limited number of samples during this phase. Since we mainly used 
the model to estimate individual values for Cl/F, the modest under-prediction of the 
absorption did not affect our analysis. The successful bootstrap procedure with 1000 
runs is shown in Table 2. The median values for PK parameters found were within 10% 
of those estimated with the final model indicating that the model is precise and reliable 
in its parameter estimation.
Table 2. Summary of model parameter estimates
Parameter














Cl/F (L/hr) 20.3 7.0 17.4 8.4 18.0 15.5 - 20.8
F 1 - 1 - 1 -
V1/F (L) 29.1 18.5 25.2 17.8 25.7 18.1 - 40.4
ka (hr
-1) 0.643 5.3 0.647 6.2 0.653 0.583 - 0.740
Q (L/hr) 60 4.7 51.1 7.3 52.1 45.5 - 59.1
V2 (L) 475 5.4 400 - 400 -
θTTT on F NA NA 0.792 6.5% 0.81 0.71 - 0.90
Inter-individual variablity
Cl/F (CV%) 38.1% 34.4 10 35.1% 30.5 11 35.0% 22.1 - 49.1%
V1/F (CV%) 87.3% 35.7 27 86.4% 35.3 27 90.5% 53.7 - 138.9%
Inter-occasion variability 
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Figure 1. Visual predictive check (VPC) of final everolimus PK model 
Exposure-toxicity relationship
The relationships between everolimus exposure and dose reductions as well as 
stomatitis and pneumonitis were examined. In total, 45% of the patients had their 
everolimus 10 mg dose reduced to a lower dose due to toxicity (Table 3). In general, 
toxicity developed within 3 months after the start of everolimus therapy. Toxicities 
leading to dose reduction included stomatitis, pneumonitis, fatigue, loss of appetite, 
diarrhea, liver and kidney toxicity and oedema. Considering stomatitis, 42.5% of the 
patients experienced any grade stomatitis and 7.5% experienced grade 3 stomatitis. In 
addition, 10% of the patients had a non-infectious pneumonitis.  
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Figure 2 shows boxplots of everolimus AUC and Ctrough in patients with and without 
dose reduction. Mean AUC0-24(SD) and Ctrough were 600(274) and 395(129) µg*hr/L and 
14.9(9.0) and 8.4(3.8) µg/L for patients with and without dose reductions respectively. 
The exposure to everolimus was significantly different between the two groups (mean 
difference in AUC -204 µg*hr/L (95%-CI; -340 to -69 µg*hr/L, P = 0.008 and mean 
difference in Ctrough  -6.5 µg/L (95%-CI; -11.2 to -1.8 P = 0.009). Figure 3 shows boxplots 
of AUCs and Ctrough in patients experiencing different grades of stomatitis. A positive 
association between everolimus exposure and stomatitis was identified (P = 0.047). The 
odd ratio for stomatitis was 1.16 (95%-CI; 1.06 to 1.26) for every 50 µg*hr/L increase 
in AUC0-24. Patients with grade 3 stomatitis had an everolimus exposure that was two 
times that of patients with ≤ 2 stomatitis (AUC0-24 896 vs. 456 µg*hr/L, P > 0.05 and Ctrough 
24.9 vs 10.3 µg/L, P > 0.05). No association of everolimus exposure with pneumonitis 
was found.
524722-L-bw-Schneider
Processed on: 9-10-2018 PDF page: 88
88
Everolimus pharmacokinetics and its exposure-toxicity relationship 















































































































































































































































































































































































































































































   
10
00












































































































































   
10
00













































































































































Processed on: 9-10-2018 PDF page: 89
89
Everolimus pharmacokinetics and its exposure-toxicity relationship 


























































































































































































































































































































































































































































































   
10
00












































































































































   
10
00













































































































































This study was primarily performed to assess the correlation between everolimus 
exposure and toxicity. Results show that patients who had their everolimus dose 
reduced due to toxicity, had significantly higher drug exposures than patients without 
the need for dose reductions. Moreover, everolimus exposure was associated with 
the probability for stomatitis and patients with grade 3 stomatitis had an everolimus 
exposure two times that of patients with ≤ 2 stomatitis. Additionally, we found that 
the presence of at least one TTT allele in the ABCB1 gene was associated with lower 
everolimus exposure due to decreased absorption.  
The present findings of a clear relationship between everolimus exposure and dose 
reductions due to toxicity and stomatitis are in line with results from other studies in 
patients with cancer treated with everolimus. Previously, it has been shown that a 2-fold 
increase in everolimus exposure increased the risk of ≥ grade 3 pulmonary events, ≥ 
grade 3 stomatitis and ≥ grade 3 metabolic events with 1.9, 1.5 and 1.3-fold respectively 
in patients with advanced solid tumors [13]. The present analysis could not confirm the 
earlier identified association of everolimus exposure with pneumonitis, but this may be 
due to the limited number of patients with pneumonitis in our study cohort. 
The fixed 10 mg dosing regimen of everolimus is based on its safety profile together 
with its pharmacodynamic effects on the mTOR dependent pathway in tumor and skin 
biopsies [14,15]. These studies suggested a dose of  ≥5 mg or ≥10 mg daily, based on 
complete inhibition of serine/threonine kinase p70S6 kinase (S6K1) or phosphorylated 
eIF-4G (peIF-4G) which are both downstream targets of mTOR. Since inhibition of peIF-
4G was only complete at the 10 mg dose level, it was advised to use the 10 mg once 
daily schedule for future clinical studies. The clinical relevance of this difference in 
inhibition of eIF-4G is however unknown and should be further investigated as higher 
dosing introduces also more toxicity.
The present study underscores the high inter-patient variability in everolimus PK which 
is in line with previous observations [8]. This is also analogue to the variability in PK 
seen for other oral targeted therapies for the treatment of cancer such as tyrosine 
kinase inhibitors (TKIs). For TKIs the evidence for relationships between systemic 
drug exposure and efficacy or toxicity endpoints is growing [16,17]. The currently 
available data suggest that an individualized dosing approach seems justified in certain 
circumstances and different studies support the feasibility of an individualized dosing 
approach for TKIs [18,19].  
In the exploration of covariates of influence on everolimus PK, the presence of at 
least one TTT haplotype was responsible for a decrease in everolimus exposure due 
to decreased absorption. Previously, the TTT haplotype has been demonstrated to 
be associated with enhanced function of the P-glycoprotein transporter and indeed 
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reduced exposure or efficacy of treatment [20-22]. However, decreased function of the 
transporter and thus increased exposure have also been reported, as well as studies 
that could not show an effect [7,23,24]. The association we found should be regarded 
as preliminary and needs further validation. If this association is confirmed, it might be 
argued whether a decrease in exposure of 21% can be considered as clinically relevant 
when taking into account the inter-patient variability in everolimus PK. 
To the best of our knowledge, we are the first to describe the population pharmacokinetics 
of everolimus 10 mg once daily in patient with cancer. Previously, population PK models 
have been described, but only within the field of transplantation medicine where 
everolimus is used in a much lower dose. Taking this and differences in modeling 
into account, pharmacokinetic parameter estimates were in agreement with those 
previously found [7].    
Everolimus exposures were assessed at day 15 of therapy and not necessarily at the 
time when adverse events occurred. This may be considered as a limitation and future 
studies should preferably measure everolimus exposure at the time that toxicity occurs. 
However, the variability in everolimus PK within a patient (intra-patient) is reported to 
be much smaller than the variability between patients [25,26]. In addition, we observed 
a constant clearance of everolimus over time. While treated at the same dose (10 mg 
once daily), this restricts the probability for large differences between the exposures 
that we have measured and the actual exposures that would have been measured at 
the moment that toxicity occurred. In addition, the study that previously described a 
correlation between everolimus exposure and toxicity, found similar results with the 
use of Ctrough at the time of toxicity or when Ctrough averaged over a given time period was 
used [13]. 
The present results both underscore the correlation between everolimus exposure and 
dose reductions due to toxicity as well as the high inter-patient variability in everolimus 
PK. These observations should be taken into account in the use of everolimus for the 
treatment of solid tumors. Preventing high drug exposures by dose individualization 
may have the potential to reduce the side effects of everolimus therapy while remaining 
its efficacy. However, prospective validation within oncology patients in necessary. 
Moreover, it has been shown that high early everolimus exposure (Ctrough >14.1 µg/L) is 
associated with longer progression free survival (PFS) and overall survival (OS) (13.3 
and 26.2 months vs. 3.9 and 9.9 months for PFS and OS respectively) in patients with 
mRCC [27]. Hence, an individualized dosing approach may also be of value for some 
patients with treatment inefficacy due to subtherapeutic exposures. On the other hand, 
in this present analysis there were also patients in need of dose reductions in whom 
the exposure to everolimus was not elevated. This finding suggest that a subpopulation 
may not benefit from dose individualization but maybe more from treatment switch if 
available. In summary, future studies are required to define the therapeutic window 
of everolimus for the treatment of different malignancies and these studies should 
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aim to optimize both treatment toxicity as well as efficacy outcomes possibly by using 
everolimus in a more individualized way. 
CONCLUSION
In conclusion, this study shows a clear association between everolimus exposure and 
dose reductions due to toxicity as well as stomatitis in patients with cancer using a 
newly developed population PK model. Our findings confirm observations from another 
study in patients with cancer and show us that everolimus is a good candidate for 
individualized dosing in patients with cancer.
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Supplementary data 3. Schematic presentation of PK model
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ABSTRACT
Background 
mTOR upregulation has been reported to be involved in the pathogenesis of thyroid 
tumors and treatment with the mTOR inhibitor everolimus has shown promising results 
in endocrine tumors. We conducted a prospective phase II clinical trial to determine the 
efficacy and safety of everolimus in patients with advanced follicular-derived thyroid 
cancer. 
Patients and methods 
Twenty-eight patients with progressive metastatic or locally advanced radioactive 
refractory differentiated thyroid cancer and 7 patients with anaplastic thyroid cancer 
were included and received everolimus 10mg orally once daily. The primary endpoint 
was disease control rate (complete (CR) + partial response (PR) + stable disease (SD) >24 
weeks). Secondary endpoints included progression free survival (PFS), overall survival 
(OS), toxicity and mutational and pharmacokinetic related outcomes (PK).
Results 
Median follow-up duration was 38 months (2-64). Seventeen patients (65%) showed 
SD, of which 15 (58%) showed SD >24 weeks. No CR or PR were observed. Median PFS 
and OS were 9 (95%CI:4-14) and 18 (95%CI:7-29) months, respectively. Survival was 
negatively influenced by the presence of bone metastases. Toxicity was predominantly 
grade 1/2 and included anemia (64%), cough (64%), stomatitis (61%) and hyperglycemia 
(61%). Duration of SD was related to everolimus exposure. The presence of somatic 
gene variants related to mTOR signaling did not clearly stratify for responses.
Conclusion Everolimus has clinically relevant antitumor activity in patients 
with advanced differentiated thyroid cancer. Given the observed disease 
control rate and the relatively low toxicity profile, further investigation of 
everolimus in sequential or combination therapy in these patients is warranted. 
Key terms
Everolimus, differentiated thyroid cancer, anaplastic thyroid cancer, phase II, clinical 
trial
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Thyroid cancer is the most prevalent endocrine malignancy, accounting for 96% of 
cancers of the endocrine system and 66% of endocrine cancer mortality in 2012 (1). 
The current incidence in Europe is 49/1,000,000 per year, with a nearly three times 
higher incidence in women (2). Thyroid cancer is a heterogeneous disease that is 
classified into differentiated thyroid carcinoma (DTC), undifferentiated (anaplastic) 
thyroid carcinoma (ATC) and medullary thyroid carcinoma (MTC). Differentiated thyroid 
carcinoma (DTC) is by far the most common (95%) subtype, and includes papillary (PTC, 
80%) and follicular (FTC, 10-15%) as well as subtypes like oncocytic thyroid carcinomas 
(FTC-OV). The majority of DTCs are slowly progressive, and, when identified at an early 
stage, frequently cured with surgical management and radioactive iodine 131-I ablation 
(RAI) therapy. However, metastatic DTC that has become inoperable or refractory to 
RAI therapy, is associated with a less favorable prognosis, as 10-year survival then 
varies between 25% to 40% (3,4). The efficacy of conventional chemotherapy in DTC 
is negligible, and chemotherapy is therefore no longer recommended in international 
guidelines (5,6). In fact, the American Thyroid Association recommends enrolling these 
patients in clinical trials. As a result of increased understanding of thyroid tumorigenesis, 
potential targets and novel therapeutic agents that target biological abnormalities 
have been identified. Until now, sorafenib and lenvatinib are the only targeted agents 
registered for the treatment of advanced DTC. Despite the improvement in PFS in a 
proportion of patients with these compounds, no effect on survival has been observed. 
Therefore, additional treatment options are needed for patients with progressive DTC.
 Recently, several genetic alterations involving tyrosine kinase signaling 
pathways have been described in the pathogenesis of thyroid cancer. Activating RAS, 
BRAF and TERT somatic gene variants, as well as RET/PTC rearrangements, lead to the 
constitutive activation of the MAP kinase pathway which in turn plays a key role in the 
process of tumor development and progression (7-9). In addition to the RET-RAS-RAF-
MAPK signaling pathway, the (PI3K)/Akt pathway is involved in the regulation of cell 
growth, proliferation and survival (10). An important down-stream effector in the PI3K/
Akt pathway is the mammalian target of rapamycin (mTOR). Activation of the mTOR 
serine/threonine protein kinase has been reported in a variety of malignant tumors with 
an estimated 70% of mTOR upregulation in all tumors (11). Furthermore, mTOR was 
demonstrated to be activated in aggressive PTC (12). Several studies report genomic 
alterations with activating effect on mTOR signaling including MTOR, TSC1, TSC2, NF1, 
PTEN and PIK3CA to induce sensitivity to mTOR inhibitors (13,14).
 As a result of this accrued understanding of the biological basis for 
(differentiated) thyroid cancer development, multiple clinical trials with multi-target 
tyrosine kinase inhibitors (TKIs) have been conducted (15). Everolimus (RAD001) is 
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an orally available derivative of rapamycin, targeting mTOR. Everolimus exerts its 
activity through high affinity interaction with an intracellular receptor protein, the 
immunophilin FKBP12. The FKBP12/RAD001 complex subsequently interacts with the 
mTOR protein kinase, inhibiting downstream signalling events involved in regulation 
of the G1 to S-phase transition (16). The use of everolimus in neuroendocrine tumors 
has shown encouraging results, both in vitro and in vivo (17-19). Recently, a phase II 
study of everolimus in patients with advanced thyroid cancer of all histologic subtypes 
(n=38), that started simultaneously with our study, reported a partial response (PR) 
and durable stable disease (SD) in 5% and 45% of patients, respectively. The median 
progression free survival (PFS) was 47 weeks (20). Another study of everolimus 
in DTC (n=31) showed one (3%) patient with a PR and 18 (58%) with durable SD. 
PFS was 16 months and one year survival was 76% (21). Wagle et al showed one 
patient diagnosed with ATC derived from FTC-OV with striking response upon 
giving everolimus due to a homozygous somatic TSC1 variant. This patient showed 
relapse when the tumor was selected for a secondary somatic MTOR variant (22). 
 Our phase II study was designed to assess the efficacy and safety of everolimus 




Eligibility criteria were the presence of per RECIST 1.1 (Response Evaluation Criteria In 
Solid Tumors) documented progressive metastases or unresectable local recurrence of 
DTC within 12 months before therapy for which RAI therapy was no longer effective, 
as indicated by prior negative post-therapeutic RAI scintigraphy (23). Patients were 
required to have undergone total thyroidectomy and RAI ablative therapy and had to be 
≥ 18 years of age with a Karnofsky performance score > 70%. Laboratory requirements 
consisted of adequate bone marrow function (absolute neutrophil count ≥ 1,500/µL, 
platelets ≥100,000/µL, hemoglobin ≥ 5.6mm/L), liver function (serum bilirubin ≤ 1.5× 
upper limit of normal (ULN), serum ALT and AST ≤ 2.5× ULN) and renal function (serum 
creatinine ≤ 2× ULN). Women of childbearing potential were required to have a negative 
serum or urinary pregnancy test within 14 days prior to the first dose of study drug. 
Patients were excluded when they had received prior targeted therapy with everolimus 
or other mTOR inhibitors. However, prior therapy with other kinase inhibitors was 
allowed.
Written informed consent was provided by all patients before enrollment in 
the trial. The study protocol was approved by the Institutional Review Board of the 
Leiden University Medical Center and performed in the university hospitals of Leiden 
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and Groningen. This study was registered at Clinical-Trials.gov (#NCT01118065).
Study design
We performed a non-randomized, open-label, multi-center, single arm phase II trial of 
everolimus in 28 patients with advanced DTC. The primary objective was to determine 
the efficacy (response rate and stable disease >24 weeks) of everolimus. Secondary 
objectives were determination of the maximum percentage of tumor reduction for 
target lesions, describing activity time to event endpoints (PFS and OS) and assessment 
of toxicity, adverse events (AEs) and relation between pharmacokinetics and response 
rate and stable disease > 24 weeks. Eligibility assessments, including a review of 
medical history and prior treatments, physical examination, and disease staging 
assessments were performed within 4 weeks prior to the first dose of everolimus. 
Baseline evaluations, comprising performance status, vital signs and laboratory tests 
were assessed within 2 weeks prior to initiation of therapy. Everolimus was administered 
at a dose of 10 mg orally once a day until disease progression, unacceptable toxicity, 
death, or patients’ own request. Objective tumor response and time of progressions 
was measured according to the RECIST criteria version 1.1 every 12 weeks (± 2 weeks) 
during the first year, thereafter every 3 months and at study discontinuation.
 Additionally, patients with progressive metastases or inoperable recurrent 
disease of undifferentiated (anaplastic, n=7) or medullary (n=7) thyroid cancer were 
included. The same inclusion and exclusion criteria were used, apart from the criteria 
on RAI therapy, since this is not applicable for undifferentiated or medullary thyroid 
cancer. Results on the MTC patients were published separately (24). 
Safety assessments were made every 4 weeks by adverse event collection, 
standard clinical and laboratory tests, and physical examinations. In case of toxicity or 
AEs requiring dose adjustments, drug dosing was interrupted or modified according 
to the protocol. The first dose reduction was to 5 mg once daily. If another dose 
reduction was needed, everolimus was dosed as 5 mg every other day. AE monitoring 
was continued for at least 4 weeks following the last dose of study treatment. The 
incidence, grade and casual relationship of adverse events were graded with the use 
of Common Terminology Criteria for Adverse Events (CTCAE, version 4.0). After study 
discontinuation, all patients were followed for survival for 4 weeks.
Laboratory parameters 
Serum thyroid stimulating hormone (TSH), free thyroxine (T4), thyroglobulin (Tg), Tg 
antibody levels and safety parameters were assessed at all visits. Safety parameters 
included a total blood count as well as serum levels of sodium, potassium and creatinin, 
lipids, coagulation and renal and liver function.
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Somatic gene variant spectrum screening 
Somatic hotspot gene variants were analyzed using a custom Ampliseq Cancer Hotspot 
Panel version 2 that targets 50 cancer related genes. Furthermore a dedicated NGS panel 
was tested targeting CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2B, CDKN2C, CDKN2D, 
NF1 and TSC1. Ion Torrent Ampliseq sequencing chemistry (Life Technologies, Foster 
City, CA was used. Libraries were prepared with 10 ng genomic DNA and each sample 
was uniquely barcoded using the IonXpress barcodes (Life Technologies). PGM 318 or 
proton P1 chips were prepared using the Ion Chef system and sequencing was performed 
at the Personal Genome Machine or the Proton, respectively (Life Technologies). Gene 
variants were analyzed in the Geneticist Assistant NGS Interpretative Workbench 
(Softgenetics, version 1.1.8). Variants were classified in 5 classes; only class 4 (Likely 
Pathogenic) and class 5 (Pathogenic) variants were reported.
Pharmacokinetics
To measure everolimus whole blood concentration levels at steady-state 
pharmacokinetics (PK), patients were admitted to the hospital for PK sampling on day 
15 of treatment. Samples were collected into EDTA-tubes at pre-dose, 1, 2, and 3 hours 
after everolimus intake. Additional PK sampling at 4, 5, 6, 7 and 8 hours after everolimus 
intake was optional for patients. Everolimus concentrations in whole blood were 
measured using a validated Ultra Performance Liquid Chromatography - Tandem Mass 
Spectrometric (UPLC-MS/MS) assay. At steady-state pharmacokinetics, Area Under 
the Concentration-time curve over the dosing interval (AUC0-24hr), trough everolimus 
concentration (Ctrough), time to reach peak concentration (Tmax), and peak concentration 
(Cmax) were determined using non-compartmental analyses in WinNonlin/Phoenix 
version 6.3 (Pharsight Corporation, St. Louis, MO). 
Statistical analysis 
Sample size was based on Fleming’s one-stage design, using a significance level (one-
sided) of 10% and 90% power (25). A response rate at 24 weeks of less than 5% (P0) 
would not be sufficient to warrant further investigation. A response rate of 20% (P1) or 
more would certainly implicate further investigation of everolimus in a phase III setting. 
This required a total of 28 differentiated thyroid cancer patients in our study (α=0.10, 
β=0.10, P=5%, P1=20%). The anaplastic thyroid cancer patients were analysed in an 
explorative cohort in this study.
Endpoints are reported as median (range) or proportions. Estimates of PFS 
(time from starting study drug to progression or death, whichever occurred first) and 
OS (time from starting study drug to the date of death of any cause) with associated 95% 
CIs were obtained using the Kaplan-Meier method. Patients that were progression free 
and/or alive at the time of data analysis were censored. Variables influencing everolimus 
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response were analyzed with binominal logistic regression. In order to determine the 
relation between everolimus exposure and efficacy, the patients were divided in two 
groups based on exposure above or below median everolimus exposure. Calculations 
were made using binominal logistic regression. The calculations were performed using 




Since only 7 patients with ATC were included, no definite conclusions could be 
drawn. Results of this study in patients with ATC were disappointing, with none of the 





A total of 28 DTC patients were included in this study investigating the effect of 
everolimus in patients with progressive radioiodine refractory unresectable recurrent 
or metastatic thyroid carcinoma. The study started May 2010 and follow-up of the study 
ended on 1 January 2016. Median follow-up period was 38 months (range 2-64 months) 
and median everolimus treatment period was 11 months (range 1-38 months).
 Baseline characteristics are listed in Table 1. Thirteen females (46%) and 15 
males (54%) were included with a median age of 64 years (range 40-75). The most 
common histological subtype was FTC-OV (28%), followed by FTC (25%), PTC (21%), 
poorly differentiated PTC  (11%) and follicular variant PTC  (7%). After revision by our 
pathologist, 1 patient (4%) turned out to have an ATC. At study entry, all patients had 
metastatic disease. Fifteen patients (54%) were previously treated with the tyrosine 
kinase inhibitor sorafenib.  
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Table 1 Baseline characteristics
All patients (n=28)
Gender (n, %) 





Age (year; median, range) 64 (40-75)
Time from diagnosis (year; median, range) 3.1 (0.4-15.7)
Histology (n, %) 
  PTC 
  FTC 
  FVPTC  
  FTC-OV   
  PDPTC     








Initial TNM stage (n, %) 
  I (T1 N0 M0) 
  II (T2 N0 M0) 
  III (T3 N0 M0) 
        (T1-3 N1a M0) 
  IVA (T1-3 N1a M0) 
           (T4a N0-1 M0) 
  IVB (T4b any N M0) 










Tumor extent at study entry (n, %) 





No. of disease sites (n, %) 
  1 
  2 





Mutational status (n, %) 
  BRAF V600E
  NRAS Q61R
  NRAS Q61H
  HRAS
  TSC1 
  CDKN1A 













Prior treatment (n, %) 
  Surgery 
  RAI therapy 
  Radiation therapy 
  Chemotherapy 







PTC papillary thyroid carcinoma, FTC follicular thyroid carcinoma FVPTC follicular variant PTC, 
PDPTC poorly differentiated PTC, ATC anaplastic thyroid carcinoma, * all 15 patients were 
previously treated with sorafenib
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All 28 patients enrolled in this study were eligible for efficacy analysis. Data on efficacy 
are presented in Table 2 and Figure 1. 
 Seventeen patients (65%) showed stable disease (SD) as best response, with 
15 (58%) having SD lasting >24 weeks. Median SD duration was 20 months (range 
2-38 months). At the time of data analysis, 4 (15%) patients still had ongoing SD. 
Patients with high (>466 µg*hr/L) everolimus whole blood concentrations tended to 
have a longer median duration of SD (30 vs 11 months, p=0.053) than patients with low 
everolimus whole blood concentrations. There were no complete (CR) or partial (PR) 
responses. Estimated median progression free survival (PFS) was 9 months (95% CI: 
4-14 months) and was longer in patients with high everolimus blood concentrations 
(22 vs 8 months, p=0.124). The median overall survival (OS) was 18 months (95% CI: 
7-29 months, p=0.272) and was not significantly influenced by everolimus whole blood 
concentrations. However, the median OS was a substantial 15 months longer in patients 
with high everolimus whole blood concentrations. Furthermore, in patients with bone 
metastases, the median PFS was significantly worse with 10 vs. 30 months, p=0.001. 
Disease progression and survival were not influenced by age, gender or mutational 
status. Changes in thyroglobulin levels did not significantly reflect clinical outcome, 
however patients with PD showed a clear increase in serum Tg levels, as can be seen in 
figure 2. 
Table 2 Efficacy analysis
Parameter        n=28
Median duration of treatment (months; range) 11 (1-38)
Median duration of follow-up (months; range) 32 (2-64)
Best response by RECIST 1.0 (n, %)
   Complete response
   Partial response
   Stable disease





Overall disease control 17 (65)
Median duration of SD (months; range)
  High everolimus blood concentration (months)




Median PFS (months; 95% CI)
  High everolimus blood concentration (months)




Median OS (months; 95% CI)
  High everolimus blood concentration (months)
  Low everolimus blood concentration (months)
  With bone metastases (months)






RECIST Response Evaluation Criteria in Solid Tumors, SD stable disease, PFS progression-free 
survival, OS overall survival.
† 15 of 17 patients showed SD >24 weeks, ‡ at time of data analysis, 4 patients still had ongoing SD.
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C Maximum reduction from baseline in the sum of the 
longest diameters of target lesions
524722-L-bw-Schneider
Processed on: 9-10-2018 PDF page: 109
109
Everolimus in patients with advanced follicular-derived thyroid cancer; 












Figure 2 Changes in thyroglobulin levels per cycle per patient response (SD vs. PD)


















Mean thyroglobulin levels over time per patient response. SD stable disease, PD progressive disease  
 
Mean thyroglobulin levels over time per patient response. SD stable disease, PD progressive 
disease 
Toxicity 
Thirteen patients (46%) required dose reduction due to toxicity (supplementary table 2). 
One patient (4%) discontinued everolimus treatment due to adverse events (AEs) as he 
developed kidney function disorders and anemia after 11 weeks of therapy. All observed 
AEs are listed in table 3. Treatment related AEs were predominantly grade 1 or 2, with 
the most common including anemia, cough, stomatitis and hyperglycemia. Grade 3 AEs 
consisted of stomatitis (11%), hypertension (11%), hypocalcaemia (7%), anemia (4%), 
hypophosphatemia (4%), anorexia (4%), and atelectasis (4%). Two grade 4 AEs were 
documented, 1 patient was hospitalized because of severe diarrhea and the other due 
to a pneumonia. A total of 10 serious AEs (SAEs) were reported, none of which could be 
related to everolimus treatment. The fast majority of AEs were controllable with dose 
reduction, medication or supporting measures. There was no relation between toxicity 
and performance state or age.  
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Table 3 Adverse events 
                                                          All
Grades Number of patients 
(% of category)
                                              Number of patients
Event                                     (% of total (n=28))          1               2                3             4
Anemia 18 (64) 5 (28) 12 (67) 1 (5)
Cough 18 (64) 17 (94) 1 (6)
Stomatitis 17 (61) 12 (71) 2 (12) 3 (18)
Hyperglycemia  17 (61) 7 (41) 7 (41)
Hypertension 15 (54) 4 (27) 8 (53) 3 (20)
Fatigue 14 (50) 11 (79) 3 (21)
Hypophosphatemia 12 (43) 4 (33) 7 (58) 1 (8)
Loss of apatite 11 (39) 8 (73) 3 (27)
Thrombopenia 11 (39) 10 (91) 1 (9)
Dyspnea 11 (36) 8 (73) 2 (18) 1 (9)
Rash 10 (36) 8 (80) 2 (20)
Peripheral edema 8 (29) 7 (88) 1 (12)
Anorexia 8 (29) 3 (38) 4 (50) 1 (12)
Pruritis 8 (29) 8 (100)
Hypocalciemia 8 (29) 2 (25) 4 (50) 2 (25)
Kidney function # 8 (29) 5 (63) 3 (37)
Diarrhea 8 (29) 5 (63) 2 (25) 1 (12)
Nausea 7 (25) 7 (100)
Other pulmonary 7 (25) 6 (86) 1 (14)
Dry skin 6 (21) 6 (100)
Haemorrhage 6 (21) 6 (100)
Hypertryglyceridemia 6 (21) 3 (50) 3 (50)
Infection 5 (18) 2 (40) 3 (60)
Constipation 5 (18) 4 (80) 1 (20)
Headache 5 (18) 5 (100)
Dysphagia 4 (14) 3 (75) 1 (25)
Hypercholesterolemia 4 (14) 1 (25) 1 (25) 2(50)
Other cardiac 3 (11) 2 (66) 1 (33)
Pneumonitis 3 (11) 2 (66) 1 (33)
Liver function # 2 (7) 1 (50) 1 (50)
Vomiting 2 (7) 2 (100)
Fever 2 (7) 2 (100)
Allergic reaction 2 (7) 1 (50) 1 (50)
DVT 1 (4) 1 (100)
Neutropenia 1 (4) 1 (100)
Pneumonia 1 (4) 1 (100)
All AEs graded according to Common Terminology Criteria for Adverse Events version 4.
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Somatic gene variant analysis
DNA for gene variant analysis was available for all 28 tumors. A total of 14 variants 
were identified in primary tumor material of 12 patients. Variants in BRAF were  most 
frequently observed with 4/6 PTC patients harboring class 5 pathogenic BRAF variants 
(2 c.1799T>A, p.(Val600Glu), 1 c.1796T>A, p(Val600Glu) and one c.1799-1801het_
delTGA). One of these patients also showed a class 4 AKT1 c.49G>A, p.(Glu17Lys) 
pathogenic variant. A total of 4 class 5 pathogenic NRAS variants (one c.182A>G, 
p.(Gln61Arg), one c.183A>T, p.(Glu61His), one c.182A>G, p.(Gln61Arg) and one 
c.182A>G, p.(Glu61Arg)), one class 5 CDKN1Ac.45_57del, p.15-19del pathogenic 
variant, one CDKN2A class 4 c.G250T, p.(Asp84Tyr) pathogenic variant and one class 
5 heterozygous TSC1 c.C163T, p.(Gln55X) pathogenic variant were seen. One patient 
harbored a class 5 HRAS c.182A>G, p.(Gln61Arg) pathogenic variant as well as a class 
4 PTEN c.404T>A, p.(Ile135Lys) pathogenic variant. No significant relation between 
mutational status and response on everolimus treatment could be determined. The one 
patient with the TSC1 variant started only seven weeks prior to his death, therefore the 
expected effects upon giving everolimus could not be monitored. However, 3/4 patients 
with a NRAS mutation and all 4 patients with a BRAF mutated tumor showed a PFS 
and OS longer than the mPFS and mOS respectively. For an overview of histology, 
mutational status and response to everolimus treatment see supplementary table 3.
Pharmacokinetics 
Four patients underwent the short PK sampling schedule; 22 patients participated in 
the extended sampling schedule. The mean concentration versus time profile with the 
95%-CI intervals per time point is shown in Figure 3. 
A summary of the everolimus pharmacokinetics is shown in supplementary table 4. 
The median (range) AUC0-24hr for everolimus was 466 µg·hr/L (259 - 1336 µg·hr/L) and 
the median Ctrough was 9.8 µg/L (5.1 - 26.3 µg/L). The median Tmax was 1.0 hours and the 
median Cmax 63.6 µg/L. An independent samples Student’s t-test showed no significant 
difference in AUC0-24hr, Ctrough, Tmax or Cmax based on either the limited or extended sample 
scheduling, and we therefore combined the data from both groups as described above. 
Due to the relative scarcity of drug concentrations in the elimination phase, we only 
used data from patients with the extended curve (n=22) to calculate T1/2. The median T1/2 
of everolimus in these patients was 18.9 hr (13.1 - 35.8 hr).
The relation between everolimus and toxicity in patients with thyroid cancer was 
recently reported in an everolimus PK analysis in a total of 42 patients with thyroid 
cancer of all histological subtypes. (26)
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Figure 3 Mean everolimus whole blood concentration time















Bars represent the 95%-CI of the mean per time point.  
 
Bars represent the 95%-CI of the mean per time point. 
DISCUSSION
This phase II study was designed to assess the efficacy, safety and PK of everolimus in 
patients with progressive radioiodine refractory unresectable recurrent or metastatic 
differentiated thyroid carcinoma. To our knowledge, this study has the longest follow-
up duration compared to other studies of everolimus in patients with thyroid cancer 
(20,21,22,23). The results of this study are promising, with 58% of patients showing 
stable disease >24 weeks. The lack of PRs is easily explained by the fact that these 
tumors are slowly progressive by nature and everolimus exerts a reduced growth and 
proliferation effect rather than a cell death effect. The mPFS and OS were 9 and 18 months 
respectively. Interestingly, patients with high everolimus whole blood concentrations 
showed a longer median PFS, duration of SD and OS compared to patients with low 
concentrations, albeit not significant. Furthermore, we found a significantly worse 
OS in patients with bone metastases. Similar results have been reported in a phase II 
trial with sorafenib in patients with advanced DTC (27). The mPFS and percentage of 
patients with durable SD found in our study are comparable to the results of the phase 
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III DECISION trial of sorafenib in patients with advanced DTC (28). The phase III SELECT 
study of lenvatinib in patients with advanced DTC showed a mPFS of 73 weeks. The 
median OS was not reached, however our median follow-up duration was twice as long 
(29).
 The results of the separately analyzed ATC patients were disappointing, with 
none of the 7 included patients showing response on everolimus treatment. Toxicity 
was comparable to other studies with everolimus in patients with thyroid cancer. 
 Somatic mutation status of genes in the mTOR pathway did not seem to stratify 
for response, even taken a patient with a TSC1 somatic variant into account. Tumours 
that are dependent on the mTOR pathway might have increased sensitivity to mTOR 
inhibition and inactivating mutations in the tumour-suppressor genes TSC1 and TSC2 
have been reported to result in mTOR-pathway activation (30-33). Recently a case report 
was published describing a patient with an advanced ATC harbouring a homozygous 
TSC2 mutation with a near complete response on everolimus treatment that lasted for 
18 months (22). Furthermore, a phase II study of everolimus in urothelial carcinoma 
reported a durable complete remission in a patient with a TSC1 mutation (34). The fact 
that the patient with a TSC1 mutation in our study did not show a good response on 
everolimus treatment is probably related to extend of disease and high progression rate 
at trial inclusion. In addition this could well be explained by the heterozygosity of the 
TSC1 mutation. Although not significant, 7/8 patients with a BRAF or NRAS mutations 
showed a PFS and OS longer than the mPFS and mOS respectively. These findings 
correspond with previous studies, reporting on enhanced sensitivity to mTOR inhibition 
in a variety of RAS/BRAF mutated tumours (13,35-36). The lack of a relation between 
genetic analyses and response had also been observed in the decision and select trials. 
One of the explanations can be that genetic analyses have been performed in primary 
tumors that have been removed years before entering this study. The heterogeneity of 
genetic alterations in metastases in advanced DTC has been described recently (37). 
 Toxicities observed in our study were mostly grade 1 and 2 and similar to 
those reported in other phase II and III studies of everolimus(20-22,38-41). Adverse 
effects were in the majority of cases manageable with dose reduction, medication or 
supplementary measures. None of the SAEs were related to everolimus treatment. 
The PK characteristics in our study are in line with those observed in other 
phase I pharmacokinetic studies investigating everolimus 10 mg once daily (42-45). The 
inter-patient variability in PK was also comparable to previous research. 
Although everolimus is a promising agent in patients with a variety of solid 
tumors, it can be hypothesized that its inability to inhibit mTORC2 results in a less 
potent antitumor effect. An in vitro study showed simultaneous inhibition of mTORC2 
during everolimus treatment resulted in greater efficacy and the prevention of requiring 
resistance (46). In addition, several studies describe a feedback loop between mTOR 
pathway and RAS/MAPK/ERK signaling, resulting in a different prosurvival signaling 
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pathway upon mTOR inhibition. Everolimus as a single target agent might therefore 
not be the most effective therapy, emphasizing the interest of studies with everolimus 
combination therapy (15,29,31,43-45).
In conclusion, given the disease control rate comparable to sorafenib, but 
everolimus’ relatively low toxicity profile, we consider everolimus to be a promising 
agent in the combination treatment of patients with advanced differentiated thyroid 
cancer and further investigation of everolimus in sequential or combination therapy is 
warranted. Currently, trials combining everolimus with TKIs are being conducted (www.
clinicaltrials.gov).  With the exception of a spectacular result reported recently in the 
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Supplementary Table 2 Reason for dose reduction and time point of onset  
Patient study no. Toxicity
No. of treatment 
cycles before onset
1 Pneumonitis gr.2 10
2 Stomatitis gr.3 1
4 Stomatitis gr.2 1
5 Fatigue gr.2 15
7 Pneumonitis gr.2 6
11 Pneumonitis gr.3 2
13 Stomatitis gr.2 1
15 Anorexia gr.2 3
17 Stomatitis gr.3 1
18 Fatigue gr.2 1
21 Fatigue gr.2 3
22 Kidney function disorder gr.2 1
26 Liver function disorder gr.3 1
Supplementary Table 3 Mutational related outcomes  





4 PTC BRAF c.1796T>A, p(Val600Glu) 97 158
8 FTC NRAS c.182A>G, p.(Gln61Arg) 28 102
9 FTC-OV CDKN2A c.G250T, p.(Asp84Tyr) 11 20
16 PTC BRAF c.1799T>A, p(Val600Glu) 143 143*+
18 PTC TSC1 c.C163T, p.(Gln55X) 6 7
19 FTC CDKN1A c.45_57del, p.15-19del 1 1
21 FVPTC NRAS c.183A>T, p.(Glu61His) 128 128*+
22 FTC NRAS c.182A>G, p.(Gln61Arg) 127 127*+









PFS progression free survival, wks weeks, OS overall survival, PTC papillary thyroid carcinoma, 
FTC follicular thyroid carcinoma, FTC-OV follicular thyroid carcinoma oncocytic type, FVPTC 
follicular variant papillary thyroid carcinoma, * patient still alive at time of data analysis, + patient 
still on everolimus treatment at time of data analysis 
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Supplementary Table 4 Summary of everolimus pharmacokinetic parameters
Median Range CV%
AUC0-24hr (µg·hr/L) 466 259 - 1336 48.0%
Ctrough (µg/L) 9.8 5.1 - 26.3 56.9%
Tmax (hr) 1.0 0.7 - 5.0 75.1%
Cmax  (µg/L) 63.6 34.8 - 116.9 39.9%
T1/2 (hours) 18.9 13.1 - 35.8 32.6%
AUC, area under the concentration time curve; Ctrough, minimum plasma concentration; Cmax, peak 
plasma concentration; CV%, coefficient of variation, T1/2, elimination half-life; Tmax, time to reach 
peak plasma concentration.
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In this thesis new treatment modalities are described in differentiated (DTC), anaplastic 
(ATC) and advanced medullary thyroid cancer (MTC). A large majority of patients with 
DTC can be cured with standard treatments, and others may survive long after initial 
disease diagnosis and treatment despite persistence of disease. However, DTC patients 
with progressive, radioiodine-resistant metastatic disease have a worse prognosis and 
the results of conventional treatment modalities (radiotherapy and/or chemotherapy) 
have been disappointing. These patients should nowadays be considered for entry 
into clinical trials with new biological agents. With new agents currently available, also 
patients with advanced MTC seem to have a much better perspective. For ATC patients, 
hopefully novel therapies will soon come available, as until now this devastating disease 
has shown to be almost resistant to any therapy. Advances in the treatment of persistent 
thyroid cancer is merely based on the molecular unraveling of the carcinogenesis 
pathways implicated in thyroid cancer. Aberrations in already classic cellular signal 
transduction pathways (e.g. RAS/RAF/MAPK) are present in high percentages of thyroid 
cancer.[1-3] Furthermore, angiogenesis pathways are mostly activated. Involvement 
of receptor tyrosine kinases, such as EGFR or c-Met were elucidated.[4] In addition, 
activating RET mutations are present in >95% of hereditary MTC and in 20–50% of 
sporadic MTC.[5] Because of the oncogenic roles of activated BRAF, RET, and RET/PTC 
kinases, the assumption was that specific targeting of these kinases could block tumor 
growth and induce senescence. As shown in multiple clinical trials targeting thyroid 
cancer, these ideas have to some extend appeared to be correct. Several promising 
agents were found for DTC and MTC.[6-43] However, the search for new agents that 
can be used in sequential or combination therapy will still be necessary, since many 
patients eventually become progressive using the now available biologicals or do not 
tolerate them. The recently much debated immunotherapy using immune checkpoint 
de-blocking might be of value in a small subset of patients with high PD-L1 expression 
in their thyroid cancer, although the mutational burden is relatively low in the majority 
of thyroid cancers. High mutational burden has shown to be correlated with efficacy 
of immune de-blocking agents in many human tumor types.[44-46] Currently a phase 
1b clinical trial with pembrolizumab, an anti-PD-1 antibody, is being conducted and 
preliminary results are promising (NCT02054806).[47]
However, there are some issues that need attention. A substantial proportion of 
patients (33%-50%) have stable disease of varying duration as best response in several 
studies. Given the indolent natural history of many of these tumors, a report of stable 
disease is of limited value. Objective response rates give information on progression, 
stabilization or shrinkage of tumors within a certain period of time, but do not correlate 
per se with overall survival. Progression-free survival or overall survival are not always 
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preferred primary endpoints in advanced thyroid cancer because of its indolent nature. 
Furthermore, the RECIST-criteria may not be the best method for tumor evaluation in 
this tumor type since anatomical imaging alone may have limitations. Only patients 
with documented progressive disease should be included in clinical trials. If this is not 
the case, the value of achieving stable disease is even further undermined and thereby 
differences in outcomes between studies may develop. For determining any lack of 
progression by changes in tumor size PET/CT evaluation may be of more value. Despite 
the rapid integration of PET with 18F-FDG in the clinical practice and the development 
of the PET Response Criteria in Solid Tumors (PERCIST 1.0), there has been relatively 
little systematic integration of PET into clinical trials of new cancer treatments.[48] The 
role of FDG-PET/CT in the evaluation of thyroid cancer patients remains unclear. Carr et 
al. reported a decrease in FDG uptake to be associated with subsequent tumor response 
and an increase with tumor progression in DTC patients treated with sunitinib.[49] 
However, similar results in patients treated with vandetanib could not be determined.
[50] Furthermore, it can be suggested that the 124I PET/CT may be more sensitive in 
case of thyroid cancer. A recent study reported a sensitivity of 92.5% and a 22.5% 
increased detection of RAI-avid lesions by 124I PET/CT compared with the planar 131I 
post-treatment scans.[51] Therefore, more research is needed to investigate the value 
of PET/CT in the treatment of advanced thyroid cancer, preferably in clinical trials.
Nowadays, mutational DNA and gene fusion screening can be performed 
on a routine basis in patients with (thyroid) cancer. Treatment with specific inhibitors 
could be initiated once actionable gene variants are present. So far, in relatively large 
studies of patients with advanced thyroid cancer, like the SELECT and DECISION trials, 
have not shown RAS or BRAF mutation related outcomes.[22,36,37] However, further 
research is needed for defining the clinical utility of molecular profile adjusted therapies 
in thyroid cancer and also in other sorts of cancer. In cooperation with The Dutch Center 
for Personalized Cancer Treatment (CPCT), the Drug Rediscovery Protocol (DRUP) study 
to determine the potential efficacy of targeted anti-cancer drugs in the treatment of 
patients with advanced cancers and a known molecular profile, is being performed 
(NCT02925234). In these studies, patients with advanced cancers who have exhausted 
standard treatment options, will be treated with commercially available targeted therapy 
matched to the patient’s molecular tumor profile.
The developments in the treatment of advanced thyroid cancer are intriguing. 
The unraveling of the molecular pathways in thyroid cancer has played a pivotal role 
in the development of targeted therapy for thyroid cancer. Since the knowledge of 
the biological basis of thyroid cancer has increased, systemic treatment options for 
metastatic DTC and MTC have changed. A great variety of treatment strategies exists 
for patients with extensively metastasized thyroid cancer, although this type of cancer 
is rare and often has a slowly progressive course. The evidence for these different 
treatment strategies is limited. To date, sorafenib and lenvatinib are available as 
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standard systemic treatment for patients with
progressive, RAI refractory DTC and vandetanib and cabozantinib for patients with 
advanced MTC. However, in case of slowly progressive disease, the side effects of 
systemic treatment can outweigh the potential benefits. Given the low incidence of 
(metastatic) thyroid carcinoma, its slowly progressive course and the potential toxicity 
of targeted therapies, the timing of initiation of therapy is a delicate issue. It is of great 
importance to take the natural course of disease into account and to value not only 
possible benefits but also toxicity before starting targeted therapy. Hence, initiation of 
systemic therapy preferably has to be discussed with a specialized centre.
In conclusion, issues that need to be further addressed in advanced thyroid 
cancer are several fold: Which radiological examination should be best used for 
detection and monitoring of advanced disease? Which response evaluation criteria 
are most suitable? What is the optimal timing of starting therapy and which primary 
endpoint should be used in clinical studies? Furthermore, to increase the accrual of 
advanced thyroid cancer patients in clinical studies, to optimize the design of protocols, 
to improve the characterization of tumor tissues, and to improve the tolerance of 
treatment, a multidisciplinary team of medical oncologists, endocrinologists, specialists 
in nuclear medicine, radiologists, surgeons, pathologists, molecular biologists and 
statisticians is highly recommended.
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The general introduction in Chapter 1 presents clinical aspects and molecular 
backgrounds of advanced thyroid cancer. In this review we have described new 
treatment modalities in advanced non-medullary differentiated thyroid cancer (DTC), 
anaplastic thyroid cancer (ATC) and advanced medullary thyroid cancer (MTC). A large 
proportion of patients with DTC are generally completely cured after surgery and 
subsequent radioactive iodine (RAI) therapy. Others may survive for decades despite 
persistent disease. However, DTC patients with progressive RAI-resistant metastatic 
disease have a worse prognosis and the results of conventional treatment modalities 
(radiotherapy and/or chemotherapy) have been disappointing. These patients should 
nowadays be considered for entry into clinical trials with new agents. With the 
new agents currently available, also advanced MTC patients seem to have better 
perspectives. For ATC patients, hopefully, combinations of targeting biologicals and/
or immunotherapy treatment modalities might pose better treatment options since this 
devastating disease has shown to be almost therapy resistant.
In Chapter 1 signal transduction and angiogenesis pathways are described 
that are operational in thyroid cancer and which form the “drivers” of such lesions. As 
for other human cancers a wave of optimism filled the oncology field with ideas that 
specific blockade of such pathways would be the way to stop tumor growth, induce 
apoptosis or senescence and obtain cure. These assumptions have partially appeared 
to be correct. Several promising agents have been identified to be used in the treatment 
of non-medullary DTC and MTC. However, the search for optimal protocols to be used 
in sequential or in combination therapy is necessary since patients eventually show 
progressive disease upon using such targeting drugs or do not tolerate them. Not 
part of this thesis is the important question whether the loss of iodine transport can 
be reinstalled upon giving targeting treatments. This thesis is divided in two parts: 
a section dealing with the multi-kinase inhibitor sorafenib and a part with the mTOR 
pathways inhibitor everolimus.
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Sorafenib (BAY-43-9006) is an orally active multikinase tyrosine kinase inhibitor (TKI) 
that activates antiangiogenic and pro-apoptotic pathways, targeting the Btype Raf kinase 
(BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged 
during transfection (RET). Sorafenib is widely approved for the treatment of patients 
with hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC) in well-
defined phases of disease. Chapter 2 describes the long-term results of a prospective 
phase II clinical trial to determine the efficacy of sorafenib in patients with advanced 
RAI refractory non-medullary DTC and MTC. Thirty-one patients with progressive 
metastatic or locally advanced radioactive iodine refractory differentiated thyroid 
cancer received sorafenib 400 mg orally twice daily. The study end points included 
response rate, progression-free survival (PFS), overall survival (OS), best response by 
Response Evaluation Criteria in Solid Tumors criteria 1.0, and toxicity. The Median PFS 
was 18 months (95% confidence interval (95% CI): 7-29 months) and median OS was 
34.5 months (95% CI: 19-50 months). Eight patients (31%) achieved a partial response 
and 11 patients (42%) showed stable disease after a median follow-up of 25 months 
(range 3.5-39 months). Data of multiple clinical trials showed that sorafenib has a 
generally well-tolerated profile of adverse events (AEs). The most commonly reported 
sorafenib related AEs in DTC include hand-foot syndrome, hypertension, weight loss, 
diarrhea and rash. Recent reports have also suggested a possible causal link between 
Sorafenib therapy and the development of cutaneous squamous cell carcinomas (SCC).
In conclusion, this study showed sorafenib to have clinically relevant antitumor activity 
in patients with progressive metastatic or locally advanced non-medullary RAI refractory 
DTC. Sorafenib can nowadays be considered as a standard option in these patients and 
since June 2015 sorafenib is also registered for the treatment of patients with thyroid 
cancer by the
European Medicines Agency (EMA).
 In Chapter 3 we describe three patients with a history of sorafenib treatment for 
advanced radioactive iodine refractory papillary thyroid cancer (two with a BRAF c.1799 
T>A and one carrying a rare c.1799-1801het_delTGA mutation) who presented with 
secondary non-cutaneous lesions. The first patient was diagnosed with a squamous cell 
carcinoma (SCC) of the tongue, the second patient with a primary adenocarcinoma of 
the lung, and the third with a SCC originating from the cricoid. Secondary analysis was 
required to show that the latter two presentations were in fact recurrent thyroid cancers. 
These findings suggest that drugs such as sorafenib may induce metaplasia/clonal 
divergence of metastatic thyroid cancer and thus cause diagnostic misclassification. 
Furthermore, sorafenib is potentially involved in the tumorigenesis of secondary non-
cutaneous SCC. These observations should now be confirmed in larger series of patients 
treated with drugs such as sorafenib.
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Until recently, surgery was accompanied by only limited curative and palliative 
treatment options for patients with MTC, emphasizing the need for new therapies. 
The mTOR inhibitor everolimus has shown encouraging results in the treatment of 
neuroendocrine tumors. Using everolimus, a significant dose-dependent inhibition in 
cell proliferation was observed in two medullary thyroid cancer cell lines [11]. As part 
of a prospective phase II study, we report on the safety and efficacy of everolimus in 
advanced MTC in Chapter 4. Seven patients with per RECIST 1.1 documented advanced 
MTC were included and received everolimus 10mg daily. The primary objective was 
determining treatment efficacy. Secondary endpoints included progression-free survival 
(PFS), overall survival (OS), toxicity, and pharmacokinetics (PK). The median follow-
up duration was 28 weeks (17–147). Five patients (71%) showed SD, of which 4 (57%) 
showed SD>24 weeks. Median PFS and OS were 33 (95%CI: 8–56) and 30 (95%CI: 15–
45) weeks, respectively. Toxicity was predominantly grade 1/2 and included mucositis 
(43%), fatigue (43%), and hypertriglyceridemia (43%). Four MTCs harbored the somatic 
RET mutation c.2753T>C, p.Met918Thr.The best clinical response was seen in a MTC 
patients with Multiple Endocrine Neoplasia type 2A patient. PK characteristics were 
consistent with phase I data. One patient exhibited extensive toxicity accompanying 
elevated everolimus plasma concentrations. In conclusion, this study suggests that 
everolimus exerts clinically relevant antitumor activity in patients with advanced MTC. 
Given the high rate of clinical benefit and the relatively low toxicity profile found in this 
MTC subgroup analysis, we believe that further investigation in larger cohorts of MTC 
patients is now warranted, using everolimus either as a single agent or in sequential or 
combination therapy.
 Many patients treated with the registered fixed 10 mg dose of everolimus once 
daily are in need of dose interruptions, reductions or treatment discontinuation due to 
severe adverse events. In Chapter 5 we determined the correlation between systemic 
everolimus exposure and toxicity. Additionally, the effect of different covariates on 
everolimus pharmacokinetics (PK) was explored. Forty-two patients with advanced 
thyroid carcinoma were treated with 10 mg everolimus once daily. Serial pharmacokinetic 
sampling was performed on days 1 and 15. Subsequently, a population PK model was 
developed using NONMEM to estimate individual PK values used for analysis of an 
exposure–toxicity relationship. Furthermore, this model was used to investigate the 
influence of patient characteristics and genetic polymorphisms in genes coding for 
enzymes relevant in everolimus PK. Patients who required a dose reduction (n =18) due 
to toxicity at any time during treatment had significant higher everolimus exposures 
[mean AUC0–24 (SD) 600 (274) vs. 395 (129) µg h/L, P = 0.008] than patients without a 
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dose reduction (n = 22). A significant association between Everolimus exposure and 
stomatitis was found (P = 0.047). The presence of at least one TTT haplotype in the 
ABCB1gene was associated with a 21 % decrease in everolimus exposure. In conclusion, 
this current study showed that dose reductions and everolimus-induced stomatitis were 
strongly associated with systemic everolimus drug exposure in patients with thyroid 
cancer. Our findings suggest that everolimus is a good candidate for individualized 
dosing in patients.
 Chapter 6 presents the results of a prospective phase II clinical trial to determine 
the efficacy and safety of everolimus in patients with advanced follicular-derived 
thyroid cancer. Twenty-eight patients with progressive metastatic or locally advanced 
radioactive refractory follicular-derived thyroid cancer and 7 patients with anaplastic 
thyroid cancer were included and received everolimus 10mg orally once daily. The 
primary endpoint was disease control rate (complete (CR) + partial response (PR) + 
stable disease (SD) >24 weeks). Secondary endpoints included progression free survival 
(PFS), overall survival (OS), toxicity, mutational related outcomes and pharmacokinetic 
related outcomes (PK). Results of this study in patients with ATC were disappointing, 
with none of the patients benefiting from treatment. In the follicular-derive group, 
median follow-up duration was 38 months (2-64). Seventeen patients (65%) showed 
SD, of which 15 (58%) showed SD > 24 weeks. No CR or PR were observed. Median PFS 
and OS were 9 (95%CI:4-14) and 18 (95%CI:7-29) months, respectively. Survival was 
negatively influenced by the presence of bone metastases. Toxicity was predominantly 
grade 1/2 and included anemia (64%), cough (64%), stomatitis (61%) and hyperglycemia 
(61%). Duration of SD was related to everolimus exposure. The presence of somatic gene 
variants related to mTOR signaling did not clearly stratify for responses. In conclusion, 
with the exception of a spectacular result reported recently in the literature, there seems 
to be no role for everolimus treatment in the majority of ATCs. However, given the 
disease control rate comparable to sorafenib, but everolimus’ relatively low toxicity 
profile, we consider everolimus to be a promising agent in the combination treatment 
of patients with advanced differentiated thyroid cancer and further investigation of 
everolimus regimens in sequential or combination therapy is warranted.
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De algemene introductie in Hoofdstuk 1 geeft een overzicht van de klinische en 
moleculaire aspecten van het gevorderde schildkliercarcinoom. In dit overzichtsartikel 
beschrijven we de nieuwe behandelingsmogelijkheden van gedifferentieerd 
non-medullair schildkliercarcinoom (NMTC), anaplastisch (ATC) en medullair 
schildkliercarcinoom (MTC). Het overgrote deel van de patiënten met gedifferentieerd 
NMTC kan worden genezen met de combinatie van operatie en radioactief jodium 
(RAI) nabehandeling, anderen leven nog tientallen jaren ondanks aanhoudende 
ziekte. Patiënten waarbij operatie niet meer zinvol is of de tumorcellen geen RAI meer 
opnemen hebben echter een slechtere prognose en de werkzaamheid van bestraling/
chemotherapie is teleurstellend. Het moet dan ook overwogen worden deze patiënten 
te includeren in klinische studies waarbij nieuwe geneesmiddelen worden getest. Met 
de inmiddels beschikbare nieuwe behandelingsmogelijkheden lijken ook patiënten met 
gevorderde MTC betere overlevingskansen te hebben. Helaas bestaan er tot op heden 
nog geen effectieve behandelopties voor het lokaal uitgebreide of gemetastaseerde 
ATC.
De grote ontwikkelingen die de afgelopen jaren hebben plaatsgevonden op het 
gebied van de behandeling van het gevorderde schildkliercarcinoom zijn te danken aan 
de toenemende kennis van de biologische basis die ten grondslag ligt aan het ontstaan 
van deze maligniteit. Afwijkingen in onder andere de zogenaamde RET/PTC-RAS-RAF-
MAPK tumoroutes zijn aanwezig in een hoog percentage van de schildkliertumoren, 
waaronder veranderingen in “tyrosine-kinases (TKs)” betrokken bij tumorgroei en 
vaatgroei zoals EGFR en c-Met. Vanwege de oncogene rol van geactiveerde BRAF, 
RET en RET / PTC kinases bestond de veronderstelling dat gericht blokkeren van 
deze kinasen tumorgroei zou kunnen afremmen cq stoppen. Zoals blijkt uit meerdere 
klinische studies bij patiënten met schildklierkanker, zijn deze veronderstellingen deels 
correct. Verscheidene veelbelovende middelen zijn de afgelopen jaren ontwikkeld voor 
de behandeling van gevorderd DTC en
MTC. Toch zal de zoektocht naar nieuwe therapieën in opeenvolgende of 
combinatietherapie nog steeds nodig zijn, aangezien patiënten uiteindelijk toch 
opflakkerende ziekte tonen of zijn de bijwerkingen niet (meer) te verdragen. Mogelijk 
kunnen deze gerichte therapieën ook de gevoeligheid voor RAI behandeling herstellen. 
Dit werd niet onderzocht in dit proefschrift. Het werk beschreven in dit proefschrift 
valt uiteen in twee delen: Enerzijds een deel betreffende het gebruik van de remmer 
sorafenib, anderzijds het gebruik van het middel everolimus.
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Sorafenib is een TK-remmer die celdeling en vaatgroei remt en door in te grijpen op 
het molecuul “BRAF”, “vascular endothelial growth factor receptor” (VEGFR) types 1 
en 2 en “rearranged during transfection” (RET). Sorafenib was al geregistreerd voor 
de behandeling van patiënten met gevorderde leverceltumoren en nierceltumoren en 
heeft inmiddels ook een registratie voor het lokaal vergevorderde of gemetastaseerde 
DTC. Hoofdstuk 2 beschrijft de lange termijn resultaten van een klinische studie naar de 
werkzaamheid van sorafenib in patiënten met een gevorderd NMTC, niet meer gevoelig 
voor RAI. Een-en-dertig patiënten met uitgezaaid of in de hals aanwezig tumorresten 
werden behandeld met 400 mg sorafenib tweemaal daags. De uitkomsten werden 
gescoord op verschillende klinische parameters, waaronder effect van behandeling, 
overleving en bijwerkingen. Acht patiënten (31%) lieten een gedeeltelijke reactie zien 
en 11 patiënten (42%) bereikten stabiele ziekte na een mediane follow-up duur van 25 
maanden (3.5-39). Bijwerkingen bestonden voornamelijk uit zenuwpijnen in handen en 
voeten, gewichtsverlies, diarree en huiduitslag. Recente data suggereren echter ook 
een mogelijk verband tussen het gebruik van sorafenib en het ontstaan van bepaalde 
huidtumoren. Concluderend liet onze studie zien dat sorafenib relevante tumor remming 
geeft bij patiënten met een vergevorderd NMTC. Sorafenib kan tegenwoordig worden 
beschouwd als een standaard behandeloptie bij
deze patiënten en is sinds juni 2015 door de European Medicines Agency (EMA) 
geregistreerd voor de behandeling van patiënten met gevorderd, RAI-ongevoelig 
gedifferentieerd NMTC.
In Hoofdstuk 3 beschrijven we drie patiënten met een voorgeschiedenis 
van sorafenib therapie vanwege een gevorderd RAI ongevoelig NMTC (twee hiervan 
toonden een BRAF c.1799 T>A genverandering en één een zeldzame c.1799-1801het_
delTGA BRAF genverandering) waarbij zich andere tumoren openbaarden. De eerste 
patiënt werd gediagnosticeerd met een tumor van de tong, de tweede patiënt met 
een longtumor, en de derde met een strottenhoofdtumor. Herhaalde tumoranalyse 
in ons instituut gebruikmakend van de nieuwste technieken toonde echter dat de 
tumoren bij de laatste twee patiënten in feite teruggekeerde schildklierkanker betrof. 
Deze bevindingen lijken te suggereren dat bij behandeling met geneesmiddelen zoals 
sorafenib veranderingen in de tumoren optreden waardoor deze bij standaard analyse 
niet meer goed worden herkend. Patiënten lopen dan het risico verkeerd behandeld 
te worden. Deze waarnemingen zullen nauwlettend moeten worden geanalyseerd in 
grotere series van kankerpatiënten met een voorgeschiedenis van behandeling met 
geneesmiddelen zoals sorafenib.
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Tot voor kort ging de operatieve behandeling van gevorderd MTC gepaard met 
beperkteverlenging van de levensverwachting voor de betrokken patiënten. Het 
geneesmiddel “mammalian target of rapamycin (mTOR) inhibitor” everolimus toonde 
eerder bemoedigende resultaten in de behandeling van neuroendocriene tumoren. 
Bovendien werd een aanmerkelijke remming van celproliferatie waargenomen in twee 
MTC cellijnen. Als onderdeel van een prospectieve fase II studie rapporteren we de 
effectiviteit en veiligheid van everolimus in gevorderd MTC in Hoofdstuk 4. Zeven 
patiënten met een vergevorderd MTC werden geïncludeerd en eenmaal daags met 
10 mg everolimus behandeld. De uitkomstmaten betroffen wederom verschillende 
klinische gegevens, als genoemd bij de sorafenib behandeling. Vijf patiënten (71%) lieten 
stabiele ziekte (SD) zien, waarvan 4 patiënten (57%) # 24 weken. Bijwerkingen betroffen 
voornamelijk slijmvliesontstekingen, moeheid en veranderingen in de stofwisseling. 
Vier MTCs toonde genveranderingen in het zogenaamde RET gen. De beste klinische 
respons werd gezien in een voor MTC erfelijke belaste patiënt lijdend aan het Multipele 
Endocriene Neoplasie syndroom type 2A. Eén patiënt toonde uitgebreide bijwerkingen 
naast abnormaal hoge bloedwaarden van everolimus bij deze patiënt. Concluderend 
suggereert deze studie dat everolimus klinisch relevante antitumor activiteit heeft in 
patiënten met gevorderd MTC. Gezien de hoge mate van klinisch voordeel en het relatief 
lage toxiciteitprofiel van everolimus is verder onderzoek in grotere patiëntengroepen 
naar de rol van everolimus, als monotherapie of in combinatietherapie, belangrijk voor 
de toekomst.
  In Hoofdstuk 5 is gekeken naar de correlatie tussen systemische blootstelling 
van everolimus en bijwerkingen in patiënten met schildklierkanker. Geneesmiddelen 
worden na opname omgezet, afgebroken en/of uitgescheiden. Dit kan verschillend zijn 
tussen patiënten en dit werd onderzocht. Tweeënveertig patiënten met een gevorderd 
schildkliercarcinoom werden behandeld met eenmaal daags 10 mg everolimus. 
Bloedmonsters werden afgenomen op dag 1 en 15. Vervolgens werd een model 
ontwikkeld waarbij bloedwaarden en bijwerkingen werden vergeleken. Ook werd 
er naar subtiele individuele genveranderingen gekeken in gene die betrokken zijn 
met de omzetting van geneesmiddelen in het lichaam. De resultaten lieten zien dat 
patiënten die vanwege bijwerkingen minder Everolimus moesten krijgen veel hogere 
bloedwaarden hadden dan patiënten waar dit niet het geval was. De bevindingen 
suggereren dat bij gebruik van het geneesmiddel everolimus individuele dosering op 
basis van bloedwaarden een reële optie is.
 
  Hoofdstuk 6 presenteert de resultaten van een studie naar de effectiviteit en 
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veiligheid van everolimus in patiënten met DTC. Achtentwintig patiënten met uitgezaaid 
of in de hals resterende hoeveelheid NMTC ongevoelig voor RAI behandeling en 7 
patiënten met ATC werden geïncludeerd en behandeld met 10 mg everolimus eenmaal 
daags. Er werd gekeken naar uitkomsten waaronder overleving, bijwerkingen en 
geneesmiddelomzettingen in het lichaam (zie boven). De resultaten van onze studie 
in de groep ATC patiënten waren teleurstellend daar geen enkele patiënt voordeel liet 
zien van behandeling met everolimus. Zeventien van de 28 patiënten (65%) in de NMTC 
groep toonden stabiele ziekte. Overleving bleek negatief beïnvloed te worden door de 
aanwezigheid van botmetastasen. Bijwerkingen betroffen bloedarmoede (64%), hoesten 
(64%), mondslijmvliesontsteking (61%) en hoge suikerspiegels in het bloed (61%). De 
duur van klinische effecten kon worden gerelateerd aan everolimus blootstelling. De 
aanwezigheid van allerlei ter zake doende genvarianten relateerde niet eenduidig voor 
de effecten. Concluderend, met uitzondering van een door anderen recent gerapporteerd 
spectaculair behandelingseffect bij een ATC patiënt, lijkt er geen rol te zijn voor 
everolimus in de behandeling van het ATC. Echter gezien de effectiviteit van everolimus 
die vergelijkbaar is met sorafenib, maar waarbij everolimus’ relatief een geringe 
hoeveelheid bijwerkingen toont, beschouwen we everolimus als een veelbelovend 
middel in de combinatietherapie van patiënten met gevorderd gedifferentieerd NMTC. 
Verder onderzoek van everolimus in opeenvolgende of combinatietherapieën is in onze 
ogen zinvol en wenselijk.
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LIST OF ABBREVIATIONS
AE  adverse event 
AKT  AKR mouse thymoma kinase 
ALAT  alanine aminotransferase  
ALK  anaplastic lymphoma kinase  
ALT  alanine aminotransferase 
ANC  absolute neutrophil count  
ASAT  aspartat aminotransferase  
ASCO  American Society of Clinical Oncology  
AST  aspartate aminotransferase 
ATC  anaplastic thyroid cancer 
ATP  adenosine triphosphate 
AUC  aria under the curve  
BCR-ABL  breakpoint cluster region-Abelson 
BM  bone metastases  
BRAF  B-type Raf kinase  
BSA  body surface area  
CD  cluster of differentiation  
CDKN  cyclin-dependent kinase inhibitor 
CEA  carcinoembryonic antigen 
CHEK2  checkpoint kinase 2 
CI  confidence interval 
CK  cytokeratin 
c-KIT  mast/stem cell growth factor receptor 
Cmax  peak concentration 
COV  coefficient of variation 
CPCT  Center for Personalized Cancer Treatment    
CR  complete response  
CT  calcitonin 
CT  computed tomography 
CTCAE  common terminology criteria for adverse events 
Cthrough  through drug concentration  
CYP  cytochrome P 
DNA  deoxyribonucleic acid 
DRUP  drug rediscovery protocol 
DTC  differentiated thyroid cancer 
DVT  deep venous thrombose 
EDTA  ethylene diamine tetra acetic acid 
EGFR  endothelial growth factor receptor  
ELM4  echinoderm microtubule-associated protein-like 4 
EMA  European medicines agency  
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EPAR  European public Assessment Report 
ERK  extracellular signal-regulated kinases 
ESMO  European Society for Medical Oncology  
F  bioavailability  
FGFR  fibroblast growth factor receptor  
FKBP  FK206 binding protein 
FLCN  folliculin 
FNA  fine needle aspirate  
FOCE  first order conditional estimation 
FTC  follicular thyroid cancer 
FTC-OV  oncocytic thyroid carcinoma  
FVPTC  follicular variant PTC 
GFPT  glutamine-fructose-6-phosphate transaminase  
HCC  hepatocellular carcinoma 
HE  hematoxylin eosin  
HER2-  human epidermal growth factor-2 negative  
HFS  hand foot syndrome 
HIF  hypoxia inducible factor 
HR  hazard ratio 
HR+  hormone receptor positive  
HRAS  V-Ha-Ras Harvey rat sarcoma viral oncogene  
hTERT  human telomerase reverse transcriptase 
IC  inhibitory concentration  
IHC  immunohistochemistry  
KRAS  Kirsten rat sarcoma viral oncogene  
LLOQ  lower limit of quantification 
MAF  minor allele frequencies  
MAPK  mitogen-activated protein kinase  
MEK  mitogen-activated protein kinase 
MET   hepatocyte growth factor receptor 
MEN2A  multiple endocrine neoplasia type 2A 
MEN2B  multiple endocrine neoplasia type 2B 
mOS  median overall survival  
mPFS  median progression free survival 
mRCC  metastatic renal cell carcinoma 
mRNA  messenger RNA 
MTC  medullary thyroid cancer 
mTOR  mammalian target of rapamycin  
mTORC2  mammalian target of rapamycin complex 2 
N   number 
NCI  national cancer institute  
NET  neuroendocrine tumor  
NF  neurofibromatosis  
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NGF  nerve growth factor  
NGS  next generation sequencing  
NHG  near-homozygous genome 
NMTC  nonmedullary throid cancer 
NONMEM nonlinear mixed-effects modeling  
NR  not reached  
NRAS  neuroblastoma rat sarcoma viral oncogene 
NSCLC  non-small-cell lung cancer 
NTRK  neurotrophic tyrosine kinase receptor 
OFV  objective function value  
OS  overall survival 
PAX  paired box  
PD  progressive disease  
PD1  programmed cell death protein 1 
PDGFR  platelet derived growth factor receptor  
PD-L1  programmed death-ligand  
1PDPTC  poorly differentiated papillary thyroid cancer 
PDTC  poorly differentiated thyroid cancer 
PET/CT  positron emission tomography and computed tomography 
PFS  progression free survival  
PGM  personal genome machine  
P-gp  P-glycoprotein 
PI3K  phosphatidylinositol-3-kinase 
PK  pharmacokinetics  
pNET  pancreatic neuroendocrine tumor 
PPM1D  protein phosphatase 1D 
PPARɣ  peroxisome proliferator-activated receptor gamma 
PR  partial response  
PRCSD  disease control rate  
PTC  papillary thyroid cancer 
PTEN  phosphatase and tensin homolog 
Pts  patients  
PXR  pregnane X receptor 
qPCR  quantitative real-time PCR 
RAF  rapidly accelerated fibrosarcoma 
RAI  radioactive iodine 
RAS  rat sarcoma 
RCC  renal cell carcinoma  
RECIST  Response Evaluation Criteria in Solid Tumors 
RET  rearranged during transfection  
ROS1  c-ros oncogene 1 
RR  response rate 
RSE  relative standard error  
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RTK  receptor tyrosine kinase  
SAE  serious adverse event  
SCC  squamous cell carcinoma  
SD  stable disease 
SD  standard deviation  
SEGA  subependymal giant cell astrocytoma  
SNP  single nucleotide polymorphism  
SPSS  statistical package for the social sciences 
STRN  striatin 
T1/2  elimination halftime  
T4  free thyroxine  
TC   thyroid cancer 
TDM  therapeutic drug monitoring  
TERT  telomerase reverse transcriptase  
TFG  transforming growth factor  
Tg  thyroglobulin 
TK  tyrosine kinase  
TKI  tyrosine kinase inhibitor  
Tmax  time to reach peak concentration  
TNM  tumor node metastases  
TP53  tumor protein 53  
TRK  tropomyosin receptor kinase 
TSC   tuberous sclerosis complex  
TSH  thyroid stimulating hormone  
TTF  thyroid transcription factor  
ULN  upper limit of normal  
UPLC-MS ultra performance liquid chromatography-tandem mass spectrometry  
VEGF  vascular endothelial growth factor 
VEGFR  VEGF receptor  
VPC  visual predictive check  
WBC  white blood count 
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